 
 A Phase 2, Randomized Double -Blind, Placebo -
Controlled, Multi -Center Study to Assess the Efficacy, 
Safety and Tolerability of Oral LPCN 1144 in Subject s 
with Nonalcoholic Steatohepatitis  (NASH)  
 
Protocol Number: LPCN 1144 -18-002 
Phase: 2  
Coordinating Inves tigator:   
IND Number: 140203   
Sponsor: Lipocine Inc.  
 
 
Version Number:  3 .0 
7 January 2020 
 
Confidentiality Statement  
This document is a confidential communication of Lipocine Inc. Acceptance of this document signifies 
agreement by the recipient that no unpublished information contained within will be published or 
disclosed to a third party without prior written approval, except that this document may be disclosed to 
an Institutional Review Board under the same conditions of confidentiality.  

LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 
Confidential  Page 2 of 93 TABLE OF CONTENTS  
STATEMENT OF COMPLIANCE  ...........................................................................................6  
1 SUMMARY OF CHANGES IN PROTOCOL VERSION 3.0  .........................................7  
2 SUMMARY OF CHANGES IN PROTOCOL VERSION 2.0  .........................................8  
3 PROTOCOL SYNOPSIS  ..................................................................................................9  
 Synopsis  ...................................................................................................................9  
 Scheme  ...................................................................................................................14  
 Schedule of Activi ties (SOA)  ................................................................................14  
4 STUDY POPULATION  ..................................................................................................19  
 Inclusion Criteria  ...................................................................................................19  
 Exclusion Criteria  ..................................................................................................19  
 Lifestyle Considerations  ........................................................................................21  
 Screen Failures  .......................................................................................................21  
5 INTRODUCTION  ...........................................................................................................22  
 Study Rationale  ......................................................................................................22  
 Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic 
Steatohepatitis (NASH)  ...............................................................................22  
 Histology, Epidemiology and Disease Course .............................................22  
 Current Treatment Options  ..........................................................................23  
 Clinical Trial Rationale  ................................................................................23  
 Rationale for Testosterone Treatment for NASH  ........................................23  
 Justification for Dose and Safety for Use in Proposed Population ........................25  
 Receptor Pharmacology  ...............................................................................25  
 Non-Clinical Toxicology .............................................................................25  
 Clinical Safety  ..............................................................................................26  
 Inclusion of D -alpha- Tocopherol Acetate  in LPCN 1144 Formulation ................27  
6 STUDY DESIGN .............................................................................................................27  
 Overall Design  .......................................................................................................27  
7 STUDY INTERVENTION ..............................................................................................28  
 Study Intervention(s) Administration  ....................................................................28  
 Study Intervention Description  ....................................................................28  
 Dosing and Administration ..........................................................................28  
 Preparation/Handling/Storage/Accountability .......................................................28  
 Acquisition and Accountability ...................................................................28  
 Formulation, Appearance, Packaging, and Labeling ...................................29  
 Product Storage and Stability .......................................................................29  
 Measures to Minimize Bias: Randomization and Blinding  ...................................29  
 Description of Enrollment ............................................................................29  
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 3 of 93 
 Randomization and Blinding Procedures .....................................................29  
 Maintenance of Trial Randomization Codes and Blinding  ..........................29  
 Procedures for Unblinding Treatment Assignment  .....................................29  
8 STUDY INTERVENTION DISCONTINUATION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL ........................................................................30  
 Discontinuation of Study Intervention  ...................................................................30  
 Participant Discontinuation/Withdrawal from the Study  .......................................30  
 Monitoring and Stopping Criteria  ..........................................................................31  
 Blood Pressure Monitoring and Stopping Criteria .......................................31  
 Creatinine Stopping Criteria  ........................................................................31  
 PSA Monitoring and Stopping Criteria ........................................................31  
 Hematocrit and Hemoglobin Monitoring and Stopping Criteria  .................32  
 Monitoring for Hepatotoxicity and Stopping Criteria for Hepatoxicity  ......33  
 Testosterone Monitoring and Stopping Criteria  ..........................................33  
 Common Terminology Criteria for Adverse Event Stopping Criteria .........33  
 Lost to Follow -Up ..................................................................................................34  
9 STUDY ASSESSMENTS AND PROCEDURES  ...........................................................34  
 Visit Schedule Overview  .......................................................................................34  
 Screening Phase for Subject requiring testosterone/androgen washout  ......35  
 Screening Visits and Baseline Data Collection  ...........................................35  
 Randomization Visit (RZ; Day1)  .................................................................37  
 On Treatment and Follow – up Visits  ..........................................................37  
 Data and Safety  Monitoring Board  (DSMB)  ..........................................................39  
 Procedure Overview ...............................................................................................39  
 Subject Questionnaires .................................................................................39  
 Liver MRI -PDFF .........................................................................................40  
 Fibros can (transient elastography)  ...............................................................41  
 Gait Speed  ....................................................................................................41  
 Hand Grip Strength Test  ..............................................................................41  
 Liver Biopsy.................................................................................................42  
 Medical and Medication History  .................................................................42  
 Physical Examination ...................................................................................43  
9.3.9  Clinic BP and Pulse Rate (PR) Measurement Methodology:  ......................43  
 Clinical Laboratory Tests  .............................................................................44  
 Screens for Drugs of Abuse and Alcohol  ....................................................44  
 Prostate -Specific Antigen (PSA) and Digital Rectal Exam .........................44  
 Testing for Adrenal Insufficiency  ................................................................45  
 Safety issues  ...........................................................................................................45  
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 4 of 93 
 Safety Concerns Related to the Therapeutic Agents ....................................45  
 Safety  Issues Related  to Liver Biopsy  ..........................................................46  
 Safety Issues Related to Specimen Repository  ............................................46  
 Adverse Events and Serious Adverse Events  ........................................................46  
 Definition of Adverse Events (AE) ..............................................................47  
 Definition of Serious Adverse Events (SAE)  ..............................................47  
 Classification of an Adverse Event  ..............................................................48  
 Time Period and Frequency for Event Assessment and Follow -Up ............48  
 Adverse Event Reporting .............................................................................49  
 Monitoring for Adverse  Events  ....................................................................49  
 Reporting of Pregnancy  ...............................................................................50  
10 STATISTICAL CONSIDERATIONS .............................................................................50  
 Outcomes  ...............................................................................................................50  
 Sample Size Determination ....................................................................................51  
 Populations for Analyses  .......................................................................................52  
 Statistical Analyses  ................................................................................................52  
 General Approach  ........................................................................................52  
 Procedures for Missing Data  ........................................................................52  
 Efficacy Analyses  ........................................................................................53  
 Safety Analyses  ............................................................................................53  
 Cardiovascular Risk Evaluation ...................................................................54  
 Other Assessments or Analysis ....................................................................54  
11 SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS  ..54 
 Regulatory, Ethical, and Study Over sight Considerations .....................................54  
 Informed Consent Process  ...........................................................................54  
 Study Discontinuation and Closure  .............................................................55  
 Confidentiality and Privacy .........................................................................55  
 Future Use of Stored Specimens and Data  ..................................................56  
 Key Roles and Study Governance  ...............................................................56  
 Safety Oversight ...........................................................................................56  
 Clinical Monitoring  ......................................................................................56  
 Quality Assurance and Quality Control  .......................................................57  
 Data Handling and Record Keeping  ............................................................57  
 Protocol Deviations  ......................................................................................58  
 Publication and Data Sharing Policy ...........................................................58  
 Conflict of Interest Policy  ............................................................................58  
 Abbreviations  .........................................................................................................59  
12 APPENDICES  .................................................................................................................61  
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 5 of 93 APPENDIX A:  INVESTIGATOR'S AGREEMENT  ..................................................62  
APPENDIX B: DILI MONITORING ALGORITHM  ............................................................64  
APPENDIX C:  CLOSE OBSERVATION FOR POTENTIAL DRUG INDUCED LIVER 
INJURY  ...........................................................................................................................65  
APPENDIX D:  ALCOHOL QUESTIONNAIRE (AUDIT)  ..................................................66  
APPENDIX E:  FUNCTIONAL ACTIVITY QUESTIONNAIRE (NHANES)  .....................70  
APPENDIX F:  INTERNATIONAL -PROSTATE SYMPTOM SCORE (I -PSS) 
QUESTI ONNAIRE  .........................................................................................................78  
APPENDIX G:  HR -QOL (SF -36) QUESTIONNAIRE  .........................................................80  
APPENDIX H:  PGI -S QUESTIONNAIRE ............................................................................85  
APPENDIX I:  PGI -C QUESTIONNAIRE  .............................................................................86  
APPENDIX J:  CHRONIC LIVER DISEASE QUESTIONNAIRE (CLDQ)  ........................87  
APPENDIX K:  SEXUAL DESIRE AND DISTRESS QUESTIONNAIRE  ..........................89  
APPENDIX L: SPONSOR SIGNATURES  ............................................................................91  
13 REFERENCES  ................................................................................................................92  
 
  
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 6 of 93 STATEMENT OF COMPLIANCE  
The trial will be carried out in accordance with International Conference on Harmoni zation Good 
Clinical Practice ( ICH GCP) , applicable state, local and federal regulatory requirements , 
guidelines governing clinical study conduct and ethical principles tha t have their origin in the 
Declaration of Helsinki and the following:   
• United States (US) Code of Federal Regulations (CFR) applicable to clinical studies 
(45 CFR Part 46, 21 CFR Part 50, 21 CFR Part 56, 21 CFR Part 312, and/or 21 CFR 
Part 812)  
The protoc ol, informed consent form(s), recruitment materials, and all participant materials will 
be submitted to the Institutional Review Board ( IRB) for review and approval.  Approval of both 
the protocol and the consent form must be obtained before any participant is enrolled.  Any amendment to the protocol will require review and approval by the IRB before the changes are implemented to the study.  In addition, a ll changes to the consent form will be IRB -approved; a 
determination will be made regarding whether  a new consent needs to be obtained from 
participants  who provided consent , using a previously approved consent form . 
Responsibilities of the clinical investigator conducting the trial are specified in Appendix  A. 
 
  
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 7 of 93 1 SUMMARY OF CHANGES IN PROTOCOL VERSION 3.0  
Version 3.0 of the LPCN 1144- 18-002 study protocol was developed to make the following 
changes to the study:  
Affec ted 
Section(s)  Summary of Revisions Made  Rationale  
3.1 
4.1 
9.3.6.1  
10.1 Inclusion Criterion #2: Biopsy eligibility 
criterion was changed . To include stage 1 fibrotic subject s with 
NAS ≥ 4  and advanced fibrosis subjects 
regardless of NAS ballooning score  in the 
study . 
3.1 
3.3 
4.1 
9.1.2.2  Inclusion Criterion #1, testosterone screening 
assessment: Subjects  without previously 
documented hypogonadal status will be eligible 
for the study if subject has a single AM 
testosterone level < 400 ng/dL  Expand the criteria of subjects eligible for 
the trial to better reflect the NASH 
population.  
3.1, 4.2 Cholecystectomy was removed from EC #18  Expand the criteria of subjects eligible for 
the trial to better reflect the NASH 
population.  
3.1 
3.3 
4.1 
9.1.2.3  
9.3.2   MRI -PDFF, DXA imaging timing and data 
analysis was updated  To allow a subject unable to undergo MRI -
PDFF or DXA imaging due health condition (e.g. claustrophobia, difficulty holding breath 
during the procedure etc.) to enter the study.  
3.1 
3.3 
4.1 Lab value targets and procedure for approval to 
proceed to biopsy have been updated; Fibroscan 
target removed.  Predictive value of Fibroscan is low in this 
obese population  
8.2 Update procedures related to Participant 
Discontinuation/Withdrawal from the Study   Clarify the procedures for subject who discontinue dosing and/or choose to 
discontinue the study  
8.3 Close monitoring and stopping criteria  have 
been u pdate d  To reflect the Endocrine Society Clinical 
Practice Guidelines ; clarification  
3.1 
3.3 
4.2 
9.1.2.1 -2 Labs thought to be spurious can be repeated  Clarification  
9.1.3 Randomization visit section is being updated to 
collect testosterone and hormones prior to 
dosing  To collect true t=0 (baseline) T levels    
9.1.4.2  
9.1.4.3  Week 12 and Week 16 visits (of the specified sections) have been  clarified and updated  To clarify which lab should be drawn with 
the fasting labs  
9.3.3  Prior to Fibroscan, subjects must not eat or drink for at least 3 hours prior to the procedure  Fibroscan accuracy is decreased if subject 
has recently eaten/drank.  
9.3.10  Table 1: Listing  of the Clinical Laboratory Tests 
for all Subject is being updated to include more tests in hematology panel. This change will not increase the amount of blood drawn from the 
subject.  To collect and analyze Complete Blood Count 
(CBC), PT and INR  along with hemoglobin 
and hematocrit  
Not 
applicable  Minor editorial changes for consistency.   
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 
Confidential  Page 8 of 93 2 SUMMARY OF CHANGES IN PROTOCOL VERSION 2.0  
Affected 
Section  Summary of Revisions Made  Rationale  
2.1; 9.1  Interim data analysis changed to primary endpoint, 
and primary endpoint analysis changed to secondary 
endpoint  To properly power this study, calculations 
are based on previous experience 
regarding the effects of LPCN 1144 on 
MRI -PDFF hepatic fat fraction  
2.1; 5.1; 
8.1.3  Subjects will be randomized in a 1:1:1 ratio  For equal weightage between active and 
placebo groups  
2.3; 8.1  Schedule of activities updated, including changes for 
DRE, serology, hormone markers, and cortisol.  Clarification, consistency, pa tient safety 
monitoring,  and reducing the testing frequency  
2.1; 3.1  Allowable timeframe for TZD/glitazones stable dose was decreased from 6 to 3 months.  To evaluate the effect  
3.2 Clarified the exclusion criteria for serum AST and 
ALT are 200 IU/L.  Further, both AST or ALT values 
should not exceed 200 IU/L and the second reading 
should not be >1.5x from the first screening value.   Per FDA’s recommendation  
3.2 Clarified both total bilirubin screening values should not exceed the upper limit of normal, and the second 
screening value should not be >1.5x from the first 
screening value.  Per FDA’s recommendation  
2.1; 3.2; 8.1; 8.3.7  Insulin, allergy shots, and vaccines are allowable injectable drugs; clarification on sliding scale insulin was added.   Clarification  
7.3 Dose reduction, and stopping parameters for creatinine, blood pressure, and testosterone were added and clarified.  Per FDA’s recommendation  
8.1.4  Changes in baseline dose of blood pressure medications or introduction of new blood pressure 
medications will be captured at each visit.  Per FDA’s recommendation  
8.2 The role of the Data Safety Monitoring Board was 
more broadly defined.  Allow the external charter to describe its 
role more specifically  
9.4.5  Subgroup analyses of the blood pressure data for subjects with/without diabetes or diagnosis of hypertension were added.  Per FDA’s recommendation  
11 Various appendices and questionnaires added  Clarification, data collection  
Not 
applicable  Minor editorial changes for consistency.   
 
  
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 9 of 93 3 PROTOCOL SYNOPSIS  
 Synopsis  
Title:  A Phase 2, Randomized Double -Blind, Placebo -Controlled, Multi -Center Study to Assess 
the Efficacy, Safety and Tolerability of Oral LPCN 1144 in Subject s with Nonalcoholic 
Steatohepatitis  (NASH)  
Study 
Description:  The study is a Phase 2, multicenter, doubl e-blinded, placebo -controlled study.  
Phase:  2 
Sites  The study site will be multi -center study.  Approximately 10 – 30 sites.  
Objectives:  
 Primary Objective: To evaluate the c hange in hepatic fat fraction from Baseline  to Week 12 
based on magnetic resonance imaging- proton density fat fraction (MRI -PDFF) 
measurements in LPCN 1144 treated subject s. 
 
Additional  Analysis:   To evaluate whether 36 weeks of treatment with LPCN 1144 (Oral 
Testosterone (T)) lowers n onalcoholic steatohepatitis  (NASH)  activity as determined from 
hepatic histology in adult men with NASH.  
 
Secondary Objectives: To evaluate the change in hepatic fat fraction from baseline  to Week 
36 based on MRI -PDFF measurements  in LPCN 1144 treated subject s. 
 
To assess tolerability of oral LPCN 1144 in the study population.  
Eligibility  Inclusion Criteria:  
1. Male between 18 and 80 years of age, inclusive  
2. Subjects with histologic evidence of NASH upon central read of a liver biopsy, defined by  
a. Stage 1 fibrosis (according to the NASH CRN staging system) with a NAFLD activity score ( NAS) greater than or equal to 4 with at least 1 
point each in inflammation and ballooning, or  
b. Advanced fibrosis (Stage 2 or 3 according to the NASH CRN staging 
system) with at least 1 point for inflammation in the NAS  
i. A historical biopsy no more than 4 months before Screening may be considered for use with medical m onitor approval if the 
following criteria are met:  
1. Stable weights between the time of the biopsy and 
Screening.  Stable weight is defined as no more than a 5% change.  
2. Is either not taking or is on stable doses of 
TZDs/glitazones for 3  months before Day 1.  
ii. Subjects without a historical biopsy may undergo liver biopsy during Screening if at least one screening AST value is ≥ 22 U/L 
and at least one screening ALT value is ≥ 30 U/L.  Approval to 
proceed with biopsy when values of AST and/or ALT are below 
these levels will require review and approval by the medical 
monitor.    
3. Background therapy for other ongoing chronic conditions, and weight should be 
stable for at least 3 months before trial enrollment. Stable weight is defined as no 
more than a 5% change.  
4. Subjects must satisfy one of the following to meet th ese criteria: 
a. A previous historical diagnosis of hypogonadism  
i. If a subject is on androgen replacement therapy, the n the  subject 
must proceed with an appropriate washout (12 weeks following 
long acting intramuscular androgen injections; 4 weeks following 
topical or buccal androgens; 3  weeks following oral androgens) 
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 10 of 93 prior to collection of baseline serum T sample.  
ii. If naïve to androgen replacement, there is no need for washout.  
b. If a subject does not have a previous hypogonadism diagnosis, a single 
screening of testosterone level < 400 ng/dL will be used as an eligibility  
criterion , and subject will be allowed to proceed to the next step of 
screening process.  
5. Naïve to vitamin E or has discontinued current treatment of vitamin E > 100 
IU/Day and completed adequate washout (at least four weeks) of prior vitamin E 
therapy  (Including vit amin E contained in multivitamins).  
6. Judged to be in good general health as determined by the investigator at screening.  
 
Exclusion Criteria: 
1. Significant alcohol  consumption  more  than 30 g/day on average,  either  currently (as 
determined by the AUDIT and Ski nner alcohol questionnaire)  or for a period  of 
more  than 3 consecutive  months  in the 5 years  prior  to screening . 
2. Inability  to reliably  quantify alcohol  intake.  
3. Biochemical, clinical  or histologic  evidence of cirrhosis on liver biopsy (stage 4 
fibrosis).  
4. Evidence of other causes of chronic liver disease determined by medical history, including alcoholic liver disease, viral hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, autoimmune hepatitis, Wilson’s disease, hemochromatos is, 
alpha -1 antitrypsin deficiency, human immunodeficiency virus, etc.  
5. Suspected or proven liver cancer.  
6. Clinically significant abnormal laboratory value, in serum chemistry, hematology, or urinalysis including but not limited to: 
• Hematocrit > ULN  
• Hemoglobin > ULN  
• PSA > 4 ng/mL  
• Serum AST or ALT > 200 IU/L  
• Serum ALP > 2 x ULN  
• Serum creatinine of 2.0 mg/dL or greater  
• Total Bilirubin > ULN  
• International normalized ratio (INR) ≥ 1.3.  
• Prolactin > ULN  
Also:  
• Clinically significant abnormal prostate digita l rectal examination (DRE) 
in the opinion of the PI  
• International Prostate Symptom Score > 19 points  
• History of stroke or myocardial infarction within the past 5 years  
• Screening systolic BP or diastolic BP above 140 mmHg or 90 mmHg, 
respectively  
If screening value is considered spurious  by the investigator , the test may be 
repeated . 
7. Subjects with evidence of worsening liver function (ALP  and GGT second 
Screening assessment value greater than the ULN and 1.5x greater than the first 
Screening assessment value.  Both AST or ALT screening values must not exceed 
200 IU/L and the second screening value must not be > 1.5x from the first 
screening va lue.  Both TB screening values must not exceed ULN and the second 
screening value must not be > 1.5x from the first screening value.   A second 
assessment will be performed no less than 14 days after the first assessment) based 
on the two initial laboratory  values used to establish the screening / baseline values.  
If baseline value is suspected to be considered spurious, the test may be . 
8. Model for End -Stage Liver Disease (MELD) score greater  than 12. 
9. Subjects with a documented history of Gilbert’s syndrome.  
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 11 of 93 10. Evidence of portal hypertension (e.g., lower than normal platelet counts, 
esophageal varices, ascites, history of hepatic encephalopathy, splenomegaly).  
11. Use of drugs historically associated with NAFLD (amiodarone, methotrexate, 
systemic glucocorticoids, t etracyclines, tamoxifen, estrogens, anabolic steroids, 
valproic acid, other known hepatotoxins) for more than 2 weeks in the 2 years prior 
to randomization.  
12. Subjects who are on a non –  stable dose of lipid- lowering drugs, diabetic and / or 
hypertensive medication in the 3 months prior to biopsy or the 3 months prior to randomization and through the end of the study.  
13. Any over -the-counter medication or herbal remedy that is being taken with an 
intent to improve hyperlipidemia must be stable for at least 3 months prior to randomization and through the end of the study.  
14. Vitamin E supplementation of greater than 100 IU/day, unless completed adequate washout for at least 4 weeks prior to Day 1 or biopsy if one is required.  
15. Inability to safely obtain a liver biopsy.  
16. History of total parenteral nutrition in the year prior to screening.  
17. History of bariatric surgery or currently undergoing evaluation for bariatric surgery.  
18. History of gastric surgery, , vagotomy, bowel resection or any surgical procedure 
that might inte rfere with gastrointestinal motility, pH or absorption.  
19. History of biliary diversion.  
20. Known positivity for antibody to Human Immunodeficiency Virus (HIV).  
21. Known heart failure of New York Heart Association class 3, or 4.  
22. Active, serious medical disease with  likely life -expectancy less than 5 years.  
23. History of current or suspected prostate or breast cancer.  
24. History of diagnosed, severe, untreated, obstructive sleep apnea.  
25. Active substance abuse, such as alcohol or inhaled or injection drugs, in the year 
prior to screening.  Insuli n, allergy shots, and vaccines are allowed.  
26. History of significant sensitivity or allergy to any androgens, including testosterone, or product excipients.  
27. History of seizures or convulsions, including alcohol or drug withdrawal se izures.  
Childhood febrile seizures are not exclusionary.  
28. Use of known strong inhibitors (e.g., ketoconazole) or inducers (e.g., dexamethasone, phenytoin, rifampin, carbamazepine) of cytochrome P450 3A 
(CYP3A) within 30 days prior to study drug administrati on and through the end of 
the study.  
29. Subjects who are currently receiving any androgens (testosterone or other androgens or androgen supplements).  
30. Use of any investigational drug within 5 half -lives of the last dose or in the past 6 
months prior to Study D ay –2 without medical monitor and/or Sponsor approval   
31. Receipt of any drug by injection within 30 days or 10 half -lives (whichever is 
longer) prior to study drug administration without M edical Monitor  and/or Sponsor 
approval.  Insulin, allergy shots, and vaccines are allowed.  
32. Subject who is not willing to use adequate contraception for the duration of the study.  
33. Any other condition, which in the opinion of the investigator would impede 
compliance or hinder completion of the study.  
34. Failure to give informed consent.  
Endpoints:  Primary Outcome Measure:  
Change in hepatic fat fraction based on MRI -PDFF measurements in LPCN 1144 treated 
subject s after 12 weeks of treatment .   
 
Key Secondary Outcome Measures:  
• Change in NASH activity evaluated via a standardized scoring of liver biopsies at 
baseline and after 36 weeks of treatment in LPCN 1144 treated subject s. 
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 12 of 93 • Change in fibrosis evaluated via NASH CRN fibrosis score of liver biopsies at baseline 
and after 36 we eks of treatment in LPCN 1144 treated subjects.  
 
Other Secondary Outcome Measures:  
• Relative c hange in hepatic fat fraction based on MRI -PDFF measurements in LPCN 
1144 treated subjects after 12 weeks of treatment.   
• Change in hepatic fat fraction based on M RI-PDFF measurements in LPCN 1144 
treated subjects after 36 weeks of treatment.   
• Relative change in hepatic fat fraction based on MRI -PDFF measurements in LPCN 
1144 treated subjects after 36  weeks of treatment.   
• NAFL D resolution of subjects who at baseli ne is at least 5% with a decrease to less than 
5% at end of study.  
• Resolution of NASH on overall histopathological reading.  Resolution of NASH is 
defined a s NAS score of 0 –1 for inflammation, 0 for ballooning, and any value for 
steatosis . 
• Change in individual NAS component scores (inflammation, ballooning, steatosis) in 
LPCN 1144 treated subjects after 36 weeks of treatment.  
• Resolution of NASH on overall histopathological reading and no worsening of liver 
fibrosis on NASH CRN fibrosis score.  
• Improvement in liver fibrosis greater than or equal to one stage (NASH CRN fibrosis 
score) .  
• Change in anthropometric measurements (weight, body mass index (BMI ), waist  to hip 
ratio, waist circumference, triceps skin fold thickness, upper arm circumference,)  in 
LPCN 1144 treated subject s. 
• Change in insulin resistance (assessed by Homeostasis Model Assessment (HOMA) ) in 
LPCN 1144 treated subject s. 
• Changes in liver enzymes  aspartate transaminase (AST) , (alanine transaminase (ALT),  
alkaline phosphatase (ALP) , gamma -glutamyltransferase (GGT), Total Bilirubin (TB) 
and Creatine Kinase (CK) in LPCN 1144 treated subject s compare to placebo . 
• Changes in non -invasive markers of fibrosis and steatosis including cytokines, leptin, 
fibrosis markers, and lipid profile  in LPCN 1144 treated subject s compare to placebo . 
• Changes in lipid parameters (triglycerides, very low -density lipoprotein cholesterol 
(VLDL -C), high- density lipoprotein cholesterol (HDL -C), low -density lipoprotein 
cholesterol (LDL -C), and free fatty acids)  in LPCN 1144 treated subject s compare to 
placebo . 
• Changes in Functional Activity (Appendix  E), Health -Related Quality of Life (HR -
QOL) as meas ured by Short Form -36 (Appendix  G), Patient Global Impression of 
Severity (PGI -S; Appendix  H), Patient Global Impression of Change Scale (PGI -C; 
Appendix I ) Chronic Liver Disease Questionnaire (CLDQ)  (Appendix  J), and Sexual 
desire and distress ( Appendix  K) questionnaire,  in LPCN 1144 treated subject s. 
• Changes in safety  laboratory parameters (clinical chemistry, hematology and 
urinalysis)  in LPCN 1144 treated subject s compare to placebo . 
Scoring of Liver 
Biopsies for Enrollment and 
Data Analysis  The tissue will be examined by light microscopy and scored based upon the NASH Clinical 
Research Network (CRN) Nonalcoholic Fatty Liver Disease (NAFLD)/NASH scoring system.  Baseline and follow -up liver biopsies will be scored by central review of the slid es. 
The scores obtained centrally will be used for study eligibility  and data analysis.  
Sample Size  Approximately 75 subject s, 1:1:1  active to placebo.  
Description of 
Study 
Intervention:  LPCN 1144 is an oral capsule formulation of testosterone undecanoate (TU) administered as 
225 mg TU two times a day for a total daily dose of 450 mg TU.  Two different 
formulations of LPCN 1144 will be evaluated, along with placebo.  
Treatment Arms  Subject s will be randomized in a 1:1:1 ratio to the following study treatments:  
• Treatment A: Oral LPCN 1144 total daily dose of 450 mg TU administered as 
BID. 
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 13 of 93 • Treatment B: Oral LPCN 1144 d -alpha tocopherol formulation, total daily dose 
of 450 mg TU administered as BID . 
• Treatment C: Oral placebo administered as BID . 
Study Duration:  36 weeks of study treatment  plus two weeks for follow up visit . 
Study Descriptio n Each participant will be in the study for a duration of 36 weeks, not including screening and 
follow up period.   
Screening Visits: Subject s will undergo a washout prior to screening period , if necessary.  
Screening periods to complete the pre -study examinations to evaluate study eligibility (See 
Schedule of Activities  (SOA) ). During Screening Visit, hepatic fat fraction will be measured 
by MRI -PDFF, and NASH will be confirmed by liver biopsy.  
 
At the Randomization Visit, subject s will be assigned to a treatment arm, and they will 
complete any outstanding study procedures.  
 Visits at Weeks 4, 8, 12, 16, 20, 24, 30, 36 and 38 will be performed to evaluate safety 
clinical laboratory tests, adverse events, and overall subject  health.  
 
Primary  Analysis will be performed after the Week 12 visit to evaluate treatment effect.  
The change in hepatic fat fraction from Baseline ( Screening Visit)  to Week 12 will be 
measured by MRI -PDFF.   
 
At Week 36, End of Treatment (EOT) and exit procedures will be  performed  including the 
NASH activity, defined from change in standardized scoring of liver biopsies at baseline and 
after 36 weeks of treatment will be assessed.  
 
At Week 38, Follow -up procedure will include  review of adverse events, PGI -S (Appendix  
H), PGI-C (Appendix  I) questionnaires, Urinalysis and blood samples for clinical 
laboratory tests including testosterone assay, hormones and related markers (see SOA).  
Monitoring for 
Prostate, 
Cardiovascular, 
and Renal 
Stopping Criteria  Subject s will be mon itored for hematocrit , hemoglobin , creatinine, prostate specific antigen 
(PSA) , and blood pressure  with added close monitoring and discontinuation criteria noted in 
section  8.3. 
Monitoring for 
Hepatotoxicity 
and Stopping 
Criteria  To minimize the risk of hepatotoxicity, aminotransferase levels will be monitored , with 
added close monitoring and discontinuation criteria noted section  8.3. 
Reduced Dose  Subject s will be monitored for liver enzymes, hemoglobin, hematocrit, blood pressure, PSA 
and testosterone  with close monitoring and discontinuation triggers ; if levels exceed target  
criteria during close monitoring , subject s will be placed on a reduced dose (study drug one 
capsule once daily).  If subject s continue to exceed target, subject  will proceed to exit 
procedures.  
 
  
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 14 of 93 
 Schem e 
Trial Design  
 
 
 
 
 
 
 
 
 
 
 
     
 Schedule of Activities (S OA) 
Randomize  
LPCN 1144 
Treatment A  
Placebo  
Treatment C 
Final Analysis , 
and Exit 
Evaluation  
Multiple Visits:  
8 Visits:  
Weeks: 4, 8, 12, 16, 20, 24, 30, 36 
Screening /Baseline : 4 -8 
Weeks  
 
Treatment: 36 Weeks  
Primary  Analysis: 12 Weeks 
LPCN 1144 
Treatment B  Week 38  Follow – up Visit  
 
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 15 of 93 Assessment / Procedure  Optional 
Washout  Screening 
Visits  Day -
56 to - 1 / 
Baseline   On Treatment  Follow -up 
Visit 
Testosterone/  
Androgen / 
Vitamin E > 100 
IU/day Washout  
-12 to - 3 weeks 
prior to 
Screening  Screening 
assessments 
are 
completed 
over multiple 
visits  Day 1  Week 4  
(Day 
28±7)  Week 8  
(Day 
56±7) Week 12  
(Day 
84±7) Week 16 
(Day 
112±7) Week 20 
(Day 
140±7) Week 24  
(Day 
168±7) Week 30  
(Day 
210±7) Week 36  
(Day 
252±7) 
EOT  Week 38 
(Day 266±7)  
Informed consent  X 1 X           
Medical history  X X X          
Review of concomitant 
medication  X X X X X X X X X X X  
Anthropomorphic 
measurements  2  X    X     X  
Review of adverse events   X X X X X X X X X X X 
Physical examination  
(D: detailed / A: 
abbreviated)  3  D A A A D* A A A A D  
Imaging  – Fibroscan 4  X    X   X  X  
Review of historical biopsy  5  X           
Imaging – MRI-PDFF 6  X    X     X  
Biopsy7  X         X  
Imaging – DXA 8  X      X   X  
Enrollment / Randomization    X          
Drug dispensing  17   X X  X  X  X   
Drug accountability / 
adherence check     X X X X X X X X  
Questionnaires              
Alcohol questionnaire  
AUDIT  and Skinner   X           
Alcohol questionnaire  
AUDIT -C      X       
Functional Activity   X         X  
I-PSS  X    X     X  
HR-QOL (SF -36)  X         X  
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 16 of 93 Assessment / Procedure  Optional 
Washout  Screening 
Visits  Day -
56 to - 1 / 
Baseline   On Treatment  Follow -up 
Visit 
Testosterone/  
Androgen / 
Vitamin E > 100 
IU/day Washout  
-12 to - 3 weeks 
prior to 
Screening  Screening 
assessments 
are 
completed 
over multiple 
visits  Day 1  Week 4  
(Day 
28±7)  Week 8  
(Day 
56±7) Week 12  
(Day 
84±7) Week 16 
(Day 
112±7) Week 20 
(Day 
140±7) Week 24  
(Day 
168±7) Week 30  
(Day 
210±7) Week 36 
(Day 
252±7) 
EOT  Week 38 
(Day 266±7)  
PGI-S  X  X X X X X X X X  
PGI-C      X     X X 
CLDQ  X         X  
Sexual Desire and 
Distress   X  X X X X X X X X  
Clinical Laboratory Tests  15             
Urinalysis  18  X X X X X X X X X X X 
Serology   X           
C-Reactive Protein, 
Fasting glucose  and 
insulin    X   X     X  
Lipid profile  9   X X X X X X X X X X 
Hematology panel  10  X X X X X X X X X X X 
HbA1c   X    X     X  
Metabolic and renal 
function panel  11  X X X X X X X X X X X 
Hepatic panel  12  X X X X X X X X X X X 
Biomarkers  13   X        X  
Testosterone assay  
(Total and calculated free 
T, SHBG)   X 14 X X X X X X X X X X 
Hormones and related 
markers  
(DHT , LH, FSH, TSH, 
SHBG)    X X X X X X X X X X 
PSA, prolactin   X  X X X X X X X X X 
Cortisol and cortisol binding 
globulin (CBG)19  X  X X X X X X X X  
Drug and alcohol screen   X  X  X   X    
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 17 of 93 DHT = dihydrotestosterone; LH = Luteinizing Hormone; FSH = Follicle Stimulating Hormone; PSA = Prostate Specific Antigen; T SH = Thyroid Stimulating Hormone; SHBG = Sex Hormone Binding 
Globulin  
 
1. For subjects requiring washout  
2. Anthropomorphic measurements: include weight, body mass index (BMI), waist to hip ratio, waist circumference, triceps skin 
fold thickness, upper arm circumference.  
3. Detailed (D) physical defined in section 9.3.8. Abbreviated (A) physical defined section 9.3.8  *Week 12 will have a detailed 
physical examination without a DRE. 
4. Fibroscan will be done on all subjects but only required for eligibility on subject without a historical biopsy within 4 months from S creening.  
5. Review of Historical Biopsy: Historical biopsy must be done within 4 months of Screening and reviewed by a central reader.   
6. MRI-PDFF should be performed prior to  randomization but not need to be performed prior to biopsy. 
7. Biopsy: Subjects without a biopsy within 4 months of S creening  may have a biopsy during Screening if at least one screening 
AST value is ≥ 22 U/L and at least one screening ALT value is ≥ 30 U/L.  Approval to proceed with biopsy when values of 
AST and/or ALT are below these levels will require review and approval by the medical monitor.  
a. Subject must meet all other eligibility criteria including qualifying testosterone and retest of hepatic panel pr ior to 
performing biopsy.  
8. Subject should meet all inclusion criteria including eligible biopsy as assessed by the central reader and qualifying testosterone levels prior to performing DXA scan.  
9. Lipid profile: total cholesterol, triglyceride, fatty acids, V LDL -C, LDL -C, HDL -C. 
10. Hematology Panel:  complete blood count (CBC) including hemoglobin and hematocrit, prothrombin time (PT), international normalized ratio (INR) . Assessment / Procedure  Optional 
Washout  Screening 
Visits  Day -
56 to - 1 / 
Baseline   On Treatment  Follow -up 
Visit 
Testosterone/  
Androgen / 
Vitamin E > 100 
IU/day Washout  
-12 to - 3 weeks 
prior to 
Screening  Screening 
assessments 
are 
completed 
over multiple 
visits Day 1 Week 4  
(Day 
28±7) Week 8  
(Day 
56±7) Week 12  
(Day 
84±7) Week 16 
(Day 
112±7) Week 20 
(Day 
140±7) Week 24  
(Day 
168±7) Week 30  
(Day 
210±7) Week 36  
(Day 
252±7) 
EOT Week 38 
(Day 266±7)  
Serum and plasma for 
banking    X   X     X  
Gait Speed and Hand Grip  16  X         X  
Study exit evaluation            X  
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 18 of 93 11. Metabolic and renal function panel: sodium, potassium, chloride, bicarbonate, calcium, phos phate, BUN, creatinine, uric acid, 
albumin, total protein, estimated glomerular filtration rate (GFR).  
12. Hepatic panel: total bilirubin  (TB), direct bilirubin, A LT, AST, ALP, GGT, Bile acid and creatine kinase (CK).   
a. The Hepatic panel is assessed at two sep arate Screening assessments to determine if a subject’s liver enzymes are 
stable.  Last  Screening assessment value will be used as baseline value.  
b. A second Screening assessment of ALT , AST, TB, and ALP will be performed no less than 14 days after the first 
Screening assessment. Values must meet criteria defined in Exclusion criteria 6.  
13. Biomarkers: Heat -Shock Protein 47 fibroblast marker  (HSP47 fibroblast marker ), Alpha -Smooth Muscle Actin ( Alpha SMA ), 
Enhanced Liver Fibrosis ( ELF), Hyaluronic Acid (HA) , N-terminal propeptide of type II I collagen  (PIIINP), Tissue inhibitor 
of metalloproteinase 1 ( TIMP -1), Transforming G rowth Factor -Beta (TGF-Beta) , Tissue Necrosis Factor -alpha ( TNF -alpha ). 
14. Testosterone Screening Assessments: Only for subj ects not previously diagnosed with hypogonadism  
a. Individual s without a diagnosis of hypogonadism are eligible for inclusion in the study with a single screening 
testosterone level < 400 ng/dL . 
b. Subject should have  prior diagnosis of hypogonadism or  confirmed  inclusionary testosterone levels prior to completing 
MRI -PDFF, liver biopsy, and DXA.  
15. If baseline value is considered  spurious, the test may be repeated.  
16. Gait speed and hand grip may be assessed for some subjects at select sites . 
17. Drug dispensing as necessary.  
18. Urinalysis consists of general routine tests – Color, appearance, specific gravity, pH, protein, blood, ketones, urobilinogen, 
glucose, bilirubin, leukocyte esterase, nitrite.  
19. Morning levels (7- 9 AM) of Cortisol and CBG will only be performed at Screening, Week 12 and Week 36. There is no time 
restriction for all other cortisol and CBG labs.  
 
 
 
 
  
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 19 of 93 4 STUDY POPULATION 
 Inclusion Criteria  
In order to be eligible to participate in this study, an individual must meet all of the following criteria: 
 
1. Male between 18 and 80 years of age, inclusive  
2. Subjects with  histologic evidence of NASH upon central read of a liver biopsy, defined by  
a. Stage 1 fibrosis (according to the NASH CRN staging system) with a NAFLD activity score (NAS) greater than or equal to 4 with at least 1 point each in inflammation and 
ballooning, or  
b. Advanced fibrosis (Stage 2 or 3 according to the NASH CRN staging system) with at least 1 point for inflammation in the NAS.  
i. A historical biopsy no more than 4 months before Screening may be considered 
for use with medical monitor approval  if the following criteria are met:  
1. Stable weights between the time of the biopsy and Screening .  Stable 
weight is defined as no more than a 5% change.  
2. Is either not taking or is on stable doses of TZDs/glitazones for 3 months 
before Day 1.  
ii. Subjects without a historical biopsy may undergo liver biopsy during Screening if 
at least one screening AST value is ≥ 22 U/L and at least one screening ALT 
value is ≥  30 U/L.  Approval to proceed with biopsy when values of AST and/or 
ALT are below these levels will require review and approval by the medical 
monitor. 
3. Background therapy for other ongoing chronic conditions, and weight should be stable for at least 3 mont hs before trial enrollment. Stable weight is defined as no more than a 5% change .
 
4. Subjects must satisfy one of the following criteria:  
a. A previous historical diagnosis of hypogonadism   
i. If androgen replacement therapy , the subject must proceed with an appropriate 
washout  (12 weeks following long acting intramuscular androgen injections; 4 
weeks following topical or buccal androgens; 3 weeks following oral androgens)  
prior to collection of baseline serum T sample . 
ii. If naïve to androgen replacement, there is no need for washout.  
b. If a subject does not have a previous hypogonadism diagnosis, a single screening of testosterone level < 400 ng/dL will be used as an eligibility criterion and subject will be allowed to proceed to the next step of screening process.  
5. Naïve to vitamin E  or has discontinued current treatment  of vitamin E  > 100 IU/Day and 
completed adequate washout  (at least four weeks)  of prior vitamin E therapy  
6. Judged to be in good general health as determined by the investigator at s creening.  
 
 Exclusion Criteria  
An individual who meets any of the following criteria will be excluded from participation in this study unless agreed upon by the Principal Investigator (PI) and the Sponsor:  
 
1. Significant  alcohol  consumption more  than 30 g/day on average,  either  currently (as determined 
by the AUDIT and Skinner alcohol questionnaire)  or for a period  of more  than 3
 consecutive  
months  in the 5 years  prior  to screening  
2. Inability  to reliably  quantify alcohol  intake.  
3. Biochemical, clinical or histologic  evidence  of cirrhosis on liver biopsy (stage 4 fibrosis) . 
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 20 of 93 4. Evidence of other causes o f chronic liver disease determined by medical history, including 
alcoholic liver disease, viral hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, 
autoimmune hepatitis, Wilson’s disease, hemochromatosis, alpha -1 antitrypsin deficiency, 
human immunodeficiency virus , etc.  
5. Suspected or proven liver cancer . 
6. Clinically significant abnormal laboratory value, in serum chemistry, hema tology, or urinalysis 
including but not limited to:  
• Hematocrit > ULN  
• Hemoglobin > ULN  
• PSA > 4 ng/mL  
• Serum AST or ALT > 200 IU/L  
• Serum ALP > 2 x ULN  
• Serum creatinine of 2.0 mg/dL or greater  
• Total Bilirubin > ULN  
• International normalized ratio (INR) ≥ 1.3.  
• Prolactin > ULN  
Also  
• Clinically significant abnormal prostate digital rectal examination (DRE) in the opinion of the PI  
• International Prostate Symptom Score > 19 points  
• History of stroke or myocardial infarction within the past 5 years  
• Screening systolic B P or diastolic BP above 140 mmHg or 90 mmHg, respectively  
If screening  value is considered spurious , the test may be repeated . 
7. Subjects with evidence of worsening liver function (ALP  and GGT second Screening assessment 
value greater than the ULN and 1.5x greater than the first Screening assessment value . The first 
and second screening values for AST or ALT must  not exceed 200 IU/L.  The first and second 
screening for TB must  not exceed th e ULN.  The second screening for AST, ALT and TB must  
not be > 1.5x the first screening value.  A second assessment will be performed no less than 14 days after the first assessment) based on the two initial laboratory values used to establish the screenin g / baseline values.  If baseline value is suspected to be considered spurious, the test may 
be repeated . 
8. Model for End- Stage Liver Disease (MELD) score greater 12 . 
9. Subject s with a documented history of Gilbert’s syndrome.  
10. Evidence of portal hypertension ( e.g., low er than normal  platelet counts, esophageal varices, 
ascites, history of hepatic encephalopathy, splenomegaly).  
11. Use of drugs historically associated with NAFLD  (amiodarone, methotrexate, systemic 
glucocorticoids, tetracyclines, tamoxifen, estrogens , anabolic steroids, valproic acid, other 
known hepatotoxins) for more than 2 weeks in the 2 years prior to randomization. 
12. Subject s who are on a non – stable dose of lipid- lowering drugs, diabetic and / or hypertensive 
medication in the 3 months prior to biopsy or the 3 months prior to randomization and through the end of the study.  
13. Any over -the-counter medication or herbal remedy that is being taken with an intent to improve 
hyperlipidemia must be stable  for at least 3 months prior to randomization and th rough the end 
of the study. 
14. Vitamin E supplementation of greater than 100 IU/day, unless completed adequate washout for at least 4 weeks prior to Day 1 or biopsy if one is required.  
15. Inability to safely obtain a liver biopsy. 
16. History of total parenteral nut rition in the year prior to screening.  
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 21 of 93 17. History of bariatric surgery or currently undergoing evaluation for bariatric surgery.  
18. History of gastric surgery, , vagotomy, bowel resection or any surgical procedure that might 
interfere with gastrointestinal motility, pH or absorption. 
19. History of biliary diversion. 
20. Known positivity for antibody to Human Immunodeficiency Virus (HIV).  
21. Known heart failure of New York Heart Association class 3, or 4.  
22. Active, serious medical disease with likely life -expectancy less than  5 years. 
23. History of current or suspected prostate or breast cancer.  
24. History of diagnosed, severe, untreated, obstructive sleep apnea.  
25. Active substance abuse, such as alcohol or inhaled or injection drugs, in the year prior to screening.  Insulin, allergy s hots, and vaccines are allowed.  
26. History of significant sensitivity or allergy to any androgens, including testosterone, or  product 
excipients.  
27. History of seizures or convulsions, including alcohol or drug withdrawal seizures.  
28. Use of known strong inhibitors  (e.g., ketoconazole) or inducers (e.g., dexamethasone, phenytoin, 
rifampin, carbamazepine) of cytochrome P450 3A (CYP3A) within 30 days prior to study drug administration and through the end of the study.  
29. Subject s who are currently receiving any androgens (testosterone or other androgens or androgen 
supplements). 
30. Use of any investigational drug within 5 half -lives of the last dose or in the past 6 months prior 
to Study Day –2 without medical monitor and/or Sponsor approval   
31. Receipt of any drug by injection within 30 days or 10 half -lives (whichever is longer) prior to 
study drug administration without MM and/or Sponsor approval. Insulin, allergy shots, and 
vaccines are allowed.  
32. Subject  who is not willing to use adequate contraception for  the duration of the study. 
33. Any other condition, which in the opinion of the investigator would impede compliance or hinder completion of the study. 
34. Failure to give informed consent . 
 
 Lifestyle Considera tions  
Some NASH subject s are treated with vitamin E or glitazone.  Because enrollment of such subject s in 
clinical trials may confound treatment effects, subject s must  either discontinue glitazone or be on stable 
doses for 3 months before enrollment.  As one of the treatment arms is vitamin E formulation, subject s 
treated with vitamin E must  washout prior to randomization (at least four weeks).  
Subjects should maintain their normal level of physical activity, diet, and lifestyle throughout the entire study (i.e., will not begin a new exercise program or participate in any unusually strenuous physical exertion).  
Subject s will be allowed to continue on prescription antihyperlipidemic agents. Subject s will be 
interviewed in a detailed fashion at screening, rand omization, and at every clinic visit to document the 
absence or stable doses of such use. If using a statin or fibrate medication, the subject  must have been on 
a stable dose in the 3 months prior to liver biopsy and must have been on a stable dose in the 3 months prior to randomization.  
 Screen Failures  
Screen failures are defined as participants who consent to participate in the clinical trial but are not subsequently randomly assigned to the study intervention or entered in the study. A minimal set of 
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 22 of 93 screen failure information will be collected to ensure transparent reporting of screen failure participants 
and to respond to queries from regulatory authorities. Minimal information includes data for any 
procedure conducted until the point of screen failure  (excluding questionnaires unless the questionnaire 
data leads to the screen failure) , including but not limited to demography, screen failure details, 
eligibility criteria, and any serious adverse event (SAE).  
Individuals who do not meet the criteria for p articipation in this trial (screen failure) because of some of 
the clinical lab values may be allowed to re -screen , subject to Medical Monitor/Sponsor approval . 
Rescreened participants will be assigned a new  participant number.  
5  INTRODUCTION 
 Study R ationale   
 Nonalcoholic F atty L iver D isease ( NAFLD) and Nonalcoholic S teatohepatitis (NASH)  
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the United States (US) and its prevalence and clinical importance is in creasing worldwide.
i,ii Recent studies 
estimate that between 30 and 40% of the population in the US, 80- 100 million Americans, is affected by 
NAFLD.iii,iv,v The number of people at risk for NAFLD is even greater given the increasing prevalence 
of obesity, diabetes and metabolic syndrome. Nonalcoholic steatohepatitis (NASH) is a frequently progressive subset of NAFLD that can be complicated by cardiovascular disease, cirrhosis and hepatocellular carcinoma (HCC).
vi,vii  There are no FDA approved drugs for NASH. 
 Histology, Epidemiology and Disease Course  
Non-alcoholic fatty liver disease is characterized by hepatic steatosis, without a history of excessive 
alcohol use, in the absence of other known liver disease.i NAFLD can be broadly classified into two 
subtypes; nonalcoholic fatty liver (NAFL), which is generally considered to be benign with negligible 
risk of progression to advanced fibrosis and liver -related mortality, and NASH, which is generally 
considered to be progressive with substantial risk of progression to advanced fibrosis, and liver -related 
mortality.viii NAFL and NASH have traditionally been considered two separate clinical entities, rat her 
than two points on a disease continuum.ix Recent studies evaluating sequential liver biopsies are 
challenging this notion.x,xi,xii  Based upon evidence derived from systematic review and meta -analysis of 
paired liver biopsy studies, both patients with NAFL  and NASH may develop progressive liver fibrosis. 
The annual fibrosis progression rate (FPR) in patients with NAFL versus NASH, with baseline stage 0 
fibrosis, was 0.07 stages versus 0.14 stages, respectively, corresponding to an average progression by 1 
stage over 14.3 versus 7.1 years, respectively.xiii Patients with NAFL and mild lobular inflammation, 
without ballooning or fibrosis (and thus not qualifying as NASH), had increased risk of disease progression compared to those without infla mmation. 
xiii Another retrospective study evaluated serial 
liver biopsies in 108 patients and found no significant difference in the proportion of fibrosis progressi on between patients with NAFL and NASH at index biopsy (37%  vs. 43%, p = 0.65).
xi  
Similarly, a recent study analyzing paired liver biopsies over  time showed that even patients with bland 
steatosis can progress to NASH, especially in the setting of metabolic risk factors.xiv 
In the western world, NAFLD is most commonly associated with obesity, metabolic syndrome and diabetes.
xv As with other metabolic conditions, NAFLD appears to have a strong genetic component. 
Both family history of diabetes and Hispanic ethnicity have been identified as risk factors. xv Metabolic 
syndrome, diabetes and advanced age have all been shown to increase the risk of liver disease progression in NAFLD patients.
xvi,xvii  
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 23 of 93 It is estimated that NASH occurs in 20% of patients with NAFLD (3 –12% of the US population).xviii, xix  
Approximately 30–40% of patients with NASH will develop fibrosis.xx,xxi,xxii,xiii  Although fibrosis 
regresses in some patients,xxiii, viii,xxiv others progress to advanced fibrosis or cirrhosis. viii,
xxvii
xxviiixxv  In fact, 
NASH is the third leading cause of cirrhosis in the US, and the third most common indication for liver 
transplant.xxvi,   In addition to cirrhosis, and the complications that accompa ny it, NASH places 
patients at risk for hepatocellular carcinoma (HCC).   
 Current Treatment Options  
There are no approved treatment options for NAFLD or NASH. Numerous clinical trials are underway with multiple products in development for the treatment of NAFLD, NASH, NASH fibrosis and NASH cirrhosis.  
 Clinical Trial Rationale  
Numerous literature reports support  a role for T therapy in management and / or treatment of NASH and 
liver cirrhosis.  The current study is planned as a preliminary proof of concept s tudy evaluating efficacy 
and tolerability of oral LPCN 1144 in the NASH subject  population. 
 Scientific R ationale for S tudy D esign  
Currently, there is no proven pharmacotherapy available for the treatment of NASH. In the current study, the Sponsor intends  to test if T benefits subject s with NASH. The  efficacy of LPCN 1144 will be 
compared to placebo. As there is no proven pharmacologi c therapy for NASH, using a placebo for 
comparative purposes is justified. 
Given the study is a Phase 2 proof of concept study, the outcome measures will be evaluated for 
comparison purpose and where applicable a superiority test will be conducted.  
LPCN 1 144, also referred to as “Oral T”, is an oral capsule product containing an ester prodrug of T, 
TU.  Testosterone undecanoate is an esterified T derivative that is orally bioavailable, unlike T which 
undergoes extensive first pass metabolism.  After oral a dministration, TU  is absorbed into systemic 
circulation primarily via the lymphatic system following incorporation into chylomicrons.
1 Once within 
systemic circulation TU  is de -esterified by plasma esterases to T and becomes available to systemic 
target tissues.  Additionally, dihydrotestosterone undecanoate  (DHTU) , formed from TU  and 
transported into systemic circulation via lymphatic absorption, also becomes de -esterified in plasma to 
dihydrotestosterone (DHT). Based on a receptor binding study, TU  and DHTU had negligible binding 
and therefore, TU  and DHTU can be thought of as “inactive transport forms” that provide systemically 
active T and DHT.  
 Rationale for Testosterone Treatment for NASH  
LPCN 1144 has a number of potential mechanisms of action that could prove to be beneficial to subject s 
with NASH and NASH cirrhosis:  
• Androgens aid in the maintenance of liver homeostasis.2 
 
 
1 Shackleford DM,  Faassen WA,  Houwing N,  Lass H,  Edwards GA,  Porter CJ,  Charman WN . Contribution of lymphatically 
transported testosterone undecanoate to the systemic exposure of testosterone after oral administration of two andriol 
formulations in conscious lymph duct -cannulated dogs.  J Pharmacol Exp Ther.  2003 Sep;306(3):925 -33. Epub 2003 Jun 13.  
2  Shen M, Shi H. S ex Hormones and Their Receptors Regulate Liver Energy Homeostasis.  International Journal of 
Endocrinology, vol. 2015, Article ID 294278, 12 pages, 2015.   
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 24 of 93 • Androgens are known to provide benefits in terms of:  
o Anti-inflammatory properties.  
o Immune -modulating properties.3 
• Androgens aid i n liver regeneration.4 
• Glucose homeostasis: increase insulin receptor, reduce insulin resistance/increase insulin 
sensitivity;5 favorable impact on glucose metabolism. 
A growing body of evidence from  nonclinical and clinical studies reported in the literature support that 
T should be evaluated a potential treatment for NASH and NASH cirrhosis :   
 
Nonclinical studies reported in the literature  
• Two nonclinical studies have investigated the effects of T on the pathogenesis of hepatic 
steatosis in intact and castrated rats fed a high -fat diet.  
o A study by Nikolaeno et al. showed that T deficiency may contribute to the severity of 
hepatic steatosis, and that T may play a protective role in hepatic steatosis and 
nonalcoholic fatty liver disease development wi thout insulin resistance 
o A study by Jia et al. showed that T suppressed endoplasmic reticulum (ER) stress, inhibited the formation of macrovesicular lipid droplets, promoted lipid export, and ameliorated steatohepatitis induced by high fat diet and castrat ion in male rats.  
• A survival study by Vic et al. found that rats treated with testosterone enanthate prior to a 90% hepatectomy had a striking difference in post -procedure survival compared to an untreated 
control, with 100% of the untreated control dying before Hour 40, while 80 % of the testosterone enanthate treated rats. survived beyond Hour 40, and of the 80% alive at Hour 40, 50% survived for a normal life span.  Additionally, liver weight was significantly higher in the testosterone enanthate treated  group, as early as 24 hours post -hepatectomy.  
 Proof of Concept Liver Fat Evaluation using MRI -PDFF  
 
Study LPCN 1021- 18-001, included an assessment of liver fat via 
Magnetic Resonance Imaging -Proton 
Density Fat Fraction (MRI -PDFF) on a cohort of Oral  T treated hypogonadal male subjects at baseline 
(MRI- 1), at interim (MRI -2: 2 months), and at end of study (MRI -3: 4 months).  The cohort included 36 
hypogonadal males, with 34 evaluable subjects who had at least one post -baseline MRI -PDFF visit.  Of 
these subjects, 62% had non- alcoholic fatty liver disease (NAFLD), defined as baseline liver fat of at 
least 5%. The study showed a 5% and 20% decrease in mean percent liver fat from b aseline to MRI -2 
and to MRI -3 respectively  in all subjects, 14% and 33% decrease in mean percent liver fat in subjects 
with MRI -PDFF measurement of >5% at baseline, and 38% and 40% decrease in mean percent liver fat 
in subjects with MRI -PDFF measurements o f >10% at baseline.   
  
Clinical studies in the literature  
• A retrospective observational cross -sectional study by Kim et al. found that patient s with serum 
T levels in the lowest quintile had an odds ratio (OR) (95% confidence interval (CI)) of 5.12 (2.43–10.77) for NAFLD ( P value, 0.0004).  
 
 
3 Malkin CJ, Pugh PJ, Jones RD, Kapoor D, Channer KS, Jones H, The Effect of Testosterone Replacement  on Endogenous 
Inflammatory Cytokines and Lipid Profiles in Hypogonadal Men. JCEM, Vol. 89 (7), July, 2004, p 3313 –  3318.  
4 Vic P, Saint -Aubert, Astre C, Bories P, Bonardet A, Descomps B, Humeau C, Joyeux H. Complete Liver Regeneration in 
One-Stage 90% He patectomized Rats Treated with Testosterone. Hepatology; 1982; Vol. 2, No. 2, p. 247.  
5 Tsai EC, Matsumoto AM, Fujimoto WY, Boyko EJ: Association of bioavailable, free, and total testosterone with insulin 
resistance: influence of sex hormone -binding globul in and body fat. Diabetes Care 2004, 27:861– 868. 
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 25 of 93 • A study by Yurci et al. evaluating the efﬁcacy and safety of T replacement on muscle strength, 
bone mineral density (BMD), body composition and gynecomastia in hypogonadal men with liver cirrhosis found that T replacemen t improves muscle strength, ameliorates gynecomastia, 
alters body fat distribution and causes upper body adiposity in hypogonadal men with cirrhosis. 
• A 12 -month, double -blinded, placebo -controlled trial by Sinclair et al. evaluating of 
intramuscular TU  in 101 men with established cirrhosis and low serum T showed that T therapy 
in men with cirrhosis and low serum T safely increases muscle mass, bone mass and hemoglobin, and reduces fat mass and HbA1c.  
 
 Justification for Do se and Safety for Use in Proposed Po pulation  
LPCN 1144 is an easy to administer oral capsule product containing TU  with a proprietary formulation 
comprised of lipids. The product is designed to enable absorption of TU  via intestinal lymphatic 
pathway. Testosterone undecanoate, is a straight chain fatty acid ester of T, which is not alkylated at the 17-alpha position. Testosterone undecanoate is converted to T by non- specific esterases that are 
abundantly present in the body.  
In summary, LPCN 1144 in as inactive agent that converts to active testosterone. Based on a 90 day 
toxicology study in dogs , the non- androgenic no observed adverse effect level (NOAEL) was identified 
as 240 mg/kg/day, translating to a dose of about 7,776 mg in an average adult male.  This level is 
approximately 17 times proposed daily human dose in the current study and therefore provides adequate support for a proof of con cept study being proposed.  
The comorbid conditions that are normally seen in the NAFLD/NASH population are consistent with the comorbid conditions of hypogonadism. Clinical evidence summarized in the Investigator  Brochure  
suggest  beneficial trends in liver -related biomarkers at a daily dose of 450 mg TU as evaluated by the 
Sponsor.  This is further supported by beneficial roles of T administration in liver cirrhotic and transplant patients as discussed in literature.  
Based on the summary above and discussion provided below, the proposed daily dose of 450 mg LPCN 1144 administered in two equal divided doses of 225 mg administered can be considered as a safe starting dose in NASH subject s. 
 Receptor Pharmacology  
Testosterone undecanoate is a bio -reversible ester prodrug of testosterone. An androgen receptor 
binding study was conducted to investigate the pharmacological activity of TU  relative to T in the in 
vitro human androgen receptor (AR) binding assay. This study showed that binding of TU  is negligible 
compared to T ( TU inhibitory concentration 50% (IC50) binding affinit y was in the order of 1.0E -04 
lower compared to testosterone) and can be considered to be inactive transport entities for delivery of testosterone.  
 Non-Clinical Toxicology  
Numerous non- clinical studies were conducted in rats, and dogs .  Repeat dose toxicity and toxicology 
studies were conducted at various dos es with the longest studies being 26 weeks in rats and the 
previously reference 90- day toxicology study in dogs, with results described below in greater detail.  
In dogs, doses of up to 1000 mg/ kg were evaluated (equivalent human dose of 35,100 mg, 
approximately 78X human daily dose). The NOAEL for non- reproductive effects was 240 mg/kg/day 
corresponding to 7,776 mg human dose (approximately 17 times proposed human dose). Hepatocellular 
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 26 of 93 effects were minimal with focal hepatocellular degeneration/necrosis and one of dog had minimal 
periportal acute/subacute inflammation and minimal bile duct hyperplasia with correlating elevations in 
ALT, AST and ALP  at the 1000 mg/kg dose, corresponding to 78X the proposed human daily dose.  
Bile duct hyperplasia was also seen in 1 animal at 240 mg/kg/ day but  was not considered to be adverse 
since the severity was minimal.   
Based on the 90 days dog toxicology study, doses of 450 mg  TU/day in human for a duration of 36 
weeks  is well justified as a starting dose.  
 
 Clinical Safety  
5.2.3.1 Prior H uman Experience - Ex-US 
In the UK, TU  is approved as an intramuscular injection (Nebido: 1000 mg TU  every 10 to 14 weeks) 
and oral (Restandol: 40 mg TU  capsule 3 to 4 times daily) dosage forms.  A post marketing cohort study 
was conducted using the UK -based General Practice Research Database (GPRD) to explore the risk of 
idiopathic liver disease in association with use of T products. The study provides data on ~8400 patients 
accounting for ~ 15600 patient years of T use over 19 years, of which oral T use accounted for ~ 1800 
patients over 19 years (~1945 person years).  Based on the findings of li ver disease or liver adenoma (or 
liver adenocarcinoma) occurrence in T users, the upper 95 % CI for event rate in users of TU  was 
0.0537 per 10,000 person -days (0 cases in 686,791 person- days) . Based on the findings of rates of 
various adverse outcomes among users of oral T was comparable or lower to other routes that are 
commercially used in the US . 
5.2.3.2 Prior Experience  with LPCN 1144: US Clinical Studies  
Sponsor conducted numerous clinical studies with LPCN 1144 (Oral T) , a total of 597 individuals were 
dosed with LPCN 1144 including 525 hypogonadal men across eight clinical studies, 6 healthy adult 
men in one clinical study, and 66 postmenopausal women across four clinical studies , at doses ranging 
75 mg TU  to 300 mg TU, with up to 52 we eks exposure .   
LPCN 1144 was generally well tolerated, and the safety findings were consistent with those observed with other TRT products.  Gastrointestinal adverse events were of low frequency.  Most adverse events that occurred were mild or moderate in  severity.  No severe cardiac or hepatic disorders occurred during 
any clinical studies  and n o deaths were reported.  
In the 52 -week clinical study, 210 subjects received LPCN 1144 treatment at a  dose with 300 mg to 600 
mg TU  daily, and 105 received T gel.   In the LPCN 1144 arm, a  total of 16  treatment -emergent serio us 
adverse events ( SAEs ) were reported for 12 LPCN 1144- treated subjects ( 5.7%)  in the clinical  study. 
The SAEs were varied in nature and n one were considered  by the investigator to be  related t o study 
drug. 
Overall, k ey laboratory parameters and other biomarkers were mostly within reference ranges and/or 
were consistent with levels observed for other approved T replacement  products. I ncreased hematocrit is 
a known androgenic effect of T  administration and mean increases  observed were minor.   
Liver and renal function tests did not reveal any safety concerns with respect to LPCN 1144, and an 
evaluation of ALT and bilirubin showed no Hy’s law ca ses in the LPCN 1144 clinical database.  
Therefore, drug induced liver injury is not expected with LPCN 1144.  
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 27 of 93 There were no excess in hypertension- associated adverse events with LPCN 1144 (1.6% and 0.8%, 
respectively) as compared to the T gel active contro l (4.8% and 1.9%, respectively).   
In summary, the overall  safety results demonstrate that LPCN 1144 ha s an acceptable safety profile.  
5.2.3.3 Prior Experience with Testosterone in Men with NASH and Liver Cirrhosis  
There is a large body of evidence supporting the role of T in NAFLD / NASH / liver cirrhosis. Prior 
clinical studies as discussed have evaluated role of administering T in both hypogonadal and eugonadal men with liver cirrhosis, and / or liver injury, as d iscussed in section 4.2.  
 Inclusion of D-alpha -Tocopher ol Acetate in LPCN 1144 Formulation  
Vitamin E ( d-alpha tocopherol acetate) i s included in one of the LPCN 1144 formulations.  I n previous 
nonalcoholic steatohepatitis (NASH) trials , d-alpha tocopherol  has been evaluated  as a potential 
treatment.  Sanyal et al. showed that d- alpha tocopherol  therapy (800 mg IU per day), as compared with 
placebo, was associated with a significantly higher rate of improvement in NASH (43% vs. 19%, 
p=0.001).xxix Therefore,  d-alpha -tocopher ol acetate ( at a dose of 800 mg IU day) was included in one of 
the LPCN 1144 formulations  in proof  of concept  LPCN 1144- 18-002 Study to  evaluate if a higher  rate of 
improvement  in NASH  is observed when  LPCN  1144 (Oral T) is used in combination  with  d-alpha 
tocopherol .  The  amount  of d-alpha tocopherol included in the LPCN  1144  formulation  is the same 
amount  evaluated  by Sanyal  et al.  At 800 IU daily  dose, d-alpha tocopherol has shown no significant  
toxicity  in adults.xxx,xxxi 
6 STUDY DESIGN  
 Overall Design  
This is a proof of concept, Phase 2, randomized, double -blind, placebo controlled, three arm study in 
adult men  with biopsy confirmed NASH .  The study will be conducted across multiple centers in the 
United States.  
Approximately 75 subject s will be randomized in 1:1:1 ratio to receive one of the following treatments:  
• Treatment A: Oral LPCN 1144 total daily dose of 450 mg TU administered as BID   
• Treatment B: Oral LPCN 1144 d- alpha tocopherol formulation, total daily dose of 450 mg 
TU administered as BID   
• Treatment C : Oral matching placebo administered as BID   
 
Subject s will undergo a screening period to determine study eligibility. As a part of sc reening, liver 
biopsies will be performed for subject s who have not had a liver biopsy within 4 months of Screening 
Visit 1.  Adult male subject s with histologic evidence of NASH will be enrolled into the study.  Baseline 
fat fraction will be measured by M RI-PDFF in all eligible subject s. 
Eligible subject s will be randomized to one of the three treatment arms.  The treatment phase will be for 
a duration of 36- weeks  (without including screening and follow up periods)  with assessments of liver 
biopsies, hepat ic fat fraction, liver enzymes, lipid levels and other safety parameters. Safety and 
tolerability will be assessed throughout the study.  A follow -up visit will be performed to a ssess adverse 
events, complete patient reported questionnaire s including PGI -C (Appendix I ), a urinalysis and to 
obtain blood samples for clinical laboratory tests including, lipid panel, hematology panel, metabolic and renal function panel, hepatic panel, Testosterone, and hormones and related markers.  
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 28 of 93 7 STUDY INTERVENTION 
 Study Intervention (s) A dministration  
 Study I ntervention Description  
The following study treatments will be administered:  
• Treatment A: Oral LPCN 1144  capsule,  total daily dose of 450 mg TU  administered as BID   
• Treatment B: Oral LPCN 1144  capsule,  d-alpha tocopherol formulation, total daily dose of 
450 mg TU administered as BID  
• Treatment C : Oral placebo capsule administered as BID   
 
Subject s may be switched to a reduced dose (LPCN 1144 or placebo) of once daily administration (one 
capsule, once daily) based on criteria described in section 8.3.  
 Dosing and Administration 
All subject s will be instructed to take Treatment A  (225 mg TU  per dose) , B (225 mg TU  per dose) , or C  
(placebo)  twice daily, approximately 12 hours apart, approximately 30 minutes after morning and 
evening meals, wit h water . If a dose is missed, the subject s should take it as soon as they remember 
(within 4 hours of missed dose). If second dose is not taken within 16 hours of the first dose of the day, 
the subject should skip that dose and resume dosing at 24 hours past the last dose .  If a subject  is 
switched to a reduced dose, the subject  should take the dose in the morning, approximately 30 minutes 
after the morning meal, with water . 
 Preparation/H andling/ Storage/ Accountability  
 Acquisition and A ccountability 
LPCN 1144 will be provided in high- density polyethylene (HDPE) bottles. Adequate supplies of study 
drug will be provided to the study center.  
The investigator or his/her designated and qualified representatives will dispense study drug only to 
subject s enr olled in the study in accordance with the protocol. The study drug must not be used for 
reasons other than that described in the protocol.  Subject s must return all unused medication and empty 
bottles to the study center .  The number of capsules returned w ill be counted and entered into the eCRF.  
Treatment compliance is calculated as follows:  % compliance = [(number of capsules dispensed –  number of capsules returned)/ number of 
capsules expected to be used] * 100  
 
The investigator must agree to comply wi th all applicable DEA laws and regulations regarding 
controlled substances as outlined in 21 CFR 1300- 1321. 
A current (running) and accurate inventory of study drug will be kept by the investigator and will include shipping invoices and the date on which s tudy drug is dispensed to the subject . An overall 
accountability of the study drug will be performed and verified by a Sponsor appointed monitor 
throughout the study and at the study site closeout visit. Upon completion or premature discontinuation of the study, all original containers (empty or containing unused study drug) will be returned to the 
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 29 of 93 Sponsor (or a designee), according to inst ructions from the S ponsor and according to local regulations. 
Labels must remain attached to the containers . 
 Formulation, Appearance, Packaging, and Labeling 
Both LPCN 1144 active treatment arms will be provided as  gelatin capsule product s that contain 225 mg 
TU per capsule.   The placebo capsules will be match ing gelatin capsules.  
Each bottle will be labeled appropriately and at minimum will contain, quantity, manufactured by, retest 
date and a caution that the product is an investigational drug.  The conta iners will not contain the 
treatment name as the study is blinded.  Instead a unique individual bottle identification number will be 
provided. 
 Product Storage and Stability  
The study drug must be stored at room temperature 15°C to 25°C (59°F to 77°F). LPCN  1144 capsules 
are listed as Drug Enforcement Administration (DEA) Schedule CIII drugs in the United States and must be handled according to applicable federal and local regulations. The study drugs are for 
investigational use only and are to be used only within the context of this study. The study drug supplied 
for this study must be maintained under adequate security and stored under the conditions specified on 
the label until dispensed for subject  use or returned to the S ponsor. 
 Measures to Minimize Bias: Randomization  and Blinding  
 Description of E nrollment  
All subject s meeting the inclusion criteria and not meeting any of the exclusion criteria will be enrolled 
into the study.  
 Randomization and B linding P rocedures   
Subject s meeting the enrollment criteria will be randomly assigned to one of the three treatment arms. 
The randomization will be carried out by central assignment. The study is a blinded study;  therefore , all 
the randomization codes will be centrally maintained and no data from the randomization will be available to Sponsor, contract research organization ( CRO) operations team, medical monitors, monitors 
or any site staff. The treatment assigned to the study subject  will not be available to anyone except pre -
identified study personnel.  
 Maintenance of T rial R andomization C odes and B linding  
All randomization c odes will be centrally assigned and stored. Each subject  will receive a unique 
treatment ID that does not directly associate with the treatment assigned.  
 Procedures for Unblinding Treatment Assignment  
The study is a double blinded study and treatments will remain masked throughout the study until all data collection has been completed .  
Every effort will be made to maintain the blinding throughout the study except in emergency situations. The assignmen t code for the treatment will not be broken without the  knowledge of the PI . 
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 30 of 93 The following conditions describe when unblinding may be allowed:  
• Severe allergic reaction: Study medication is stopped  indefinitely. The subject , primary care 
provider (PCP), and the investigator will be  unblinded.  
• Pregnancy in partner during the study: Study medication will be stopped indefinitely, and the 
coded  medication will be unblinded. The subject , PCP, and investigator will be notified of 
the assigned treatment and the asso ciated risks in the partner . 
In unforeseen situations where the clinical center PI considers unblinding is  in the best interest of the 
participant’s health and well-being, unblinding may be done after notifying the Sponsor and/or medical 
monitor . The DSMB will review all instances of unblinding that occur. 
8 STUDY INTERVENTION DISCONTINUATION AND PARTICIPANT  
DISCONTINUATION/ WITHDRAWAL  
 Discontinuation  of Study Intervention  
Discontinuation from LPCN 1144 does not mean discontinuation from the study, and remaining study 
procedures should be completed as indicated by the study protocol.  If a clinically sig nificant finding is 
identified ( including, but not limited to changes from baseline) after enrollment, the investigator or 
quali fied designee will determine if any change in participant management is needed  (see section 8.3 for 
stopping criteria) . Any new clinically relevant finding will be reported as an a dverse event (AE) . 
The data to be collected at the time of study intervention discontinuation will include the following: 
• Biomarker and clinical safety markers samples . 
• Adverse events .  
• Investigational product return. 
 
 Participant  Discontinuation /Withdrawal  from the S tudy  
All subject s are free to withdraw from the study at any time; additionally, subject s may be withdrawn 
from the study at the discretion of the investigator if they meet any of the following criteria:  
• Any event, in the judgment of the investigator, where continuation of the subject  in the trial 
could put the subject  at health risk  (specific events are discussed in section 8.3) .  Additionally, i f 
a subject experience  any of the following serious  adverse events associated with T use during the 
trial, then study drug should be discontinued:  
a. Venous thromboembolism  
b. Myocardial infarction  
c. Stroke  
d. Edema with or without congestive heart failure, as a complication in subject s with 
cardiac, renal and hepatic disease  
e. New onset of any malignancy.  Exceptions may be approved by PI, such as basal cell 
carcinoma of the skin.  
f. If a subject  develops new onset or worsening of sleep apnea.  
• Significant noncompliance with the protocol requirements. 
• Lost to follow -up. 
 
Any subject who requires permanent discontinuation of the study drug will be followed at the scheduled 
procedures according to the protocol until at least the end of the study. If a subject  is discontinued from 
the study with an ongoing AE or an unresolved laboratory result that is in the opinion of the investigator 
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 31 of 93 is significantly outside of the reference range, the investigator will attempt to provide follow -up until a 
satisfactory clinical resolution of the AE  or laboratory result  is achieved . 
If a subj ect chooses to discontinue the study, Week 36 procedures should be completed if the subject is 
willing.  
The reason for participant discontinuation or withdrawal from the study will be recorded on the Case 
Report Form (CRF). Subject s who sign the informed c onsent form and are randomized but do not 
receive the study intervention may be replaced.  Subject s who sign the informed consent form, and are 
randomized and receive the study intervention, and subsequently withdraw, or are withdrawn or discontinued from the study, will not be replaced.  
 Monitoring and Stopping Criteria  
Baseline for Safety assessments is the Day 1 pre- dose values  or last screening value . 
 Blood Pressure Monitoring and Stopping Criteria  
Subjects will be monitored for Blood Pressure exceeding 140/90 mmHg throughout the study.  Standard clinical care should be provided to treat blood pressure.  
Close Monitoring  
While under standard clinical care, if blood pressure cannot be adequately controlled, the subject must be discontinued from study medic ation  until stabilization and a level of <140/90 mmHg is achieved 
prior to resumption of the study medication. 
Stopping Criteria  
While under standard clinical care, if blood pressure exceeds 160/100 mmHg, an immediate repeat assessment should be performed, to confirm elevation of blood pressure.  If confirmed, the subject must stop study medication and should be urgently treated.  Creatinine Stopping Criteria  
 Creatinine Stopping Criteria  
Subjects will be monitored for Creatinine throughout the study.  Stopping criteria for Creatinine are provided below:  
Stopping Criteria  
For Creatinine, an i ncrease in Creatinine  > 2 m g/dL will be used as stopping criteria . Creatinine > 2 
mg/dL will initiate a discussion with the medical monitor and initiation of clinical workup. PSA Monitoring and Stopping Criteria  
 PSA Monitoring and Stopping Criteria  
Subject s will be monitored for PSA throughout the study.  Close monitoring and stopping criteria for 
PSA are provided below:  
Close Monitoring  
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 32 of 93 Subject s with a change from baseline > 1.4 ng/ml will trigger close monitoring procedures.  The subject  
should have the PSA measured again within one week.  If the PSA value is still > 1.4 ng/ml from 
baseline, then subject  will be switche d to a reduced dose (LPCN 1144 or placebo) of once daily 
administration (one capsule, once daily).  
Stopping Criteria  
For PSA, an i ncrease in PSA > 4 ng/mL  will be used as stopping criteria . Subject s with PSA > 4 ng/mL 
should have the PSA measured again wit hin one week.  If the PSA > 4 ng/mL  value is repeated , the 
subject  will have study drug discontinued, and will proceed to exit procedures.  
 Hematocrit  and Hemoglobin Monitoring and Stopping Criteria   
Plasma Volume Depletion  
Subject s who develop elevated hematocrit of 52% during the study must  be evaluated to ascertain if the 
elevation is due to plasma volume depletion.  If the subject  has experienced recent symptoms of postural 
dizziness, fatigue, confusion, muscle cramps, chest pai n, abdominal pain, postural hypotension, or 
tachycardia or has recently experienced hemorrhage, vomiting, diarrhea, or diuresis, then schedule  
weekly hematocrit and hemoglobin tests , with a reassessment of subject  symptoms until levels return to 
target.  
Subject s will be monitored for hematocrit  and hemoglobin throughout the study.  Close monitoring and 
stopping criteria for hematocrit and hemoglobin are provided below:  
Close Monitoring  and Stopping : Hematocrit  
The ULN for hematocrit is 52% according to our reference laboratory. Subject s with  hematocrit > 52 % 
(ULN)  during the study will trigger the following close monitoring procedures.   
 
• Hematocrit > 52% (ULN): Confirm that subject is hydrated and retest the hematocrit as soon as possible, ideally within 48 hours . 
• Hematocrit > 52% (ULN) on two consecutive assays: dose reduction (once daily dosing) will be initiated  
o Weekly monitoring of hematocrit for subjects on once -daily dosing  
o Phlebotomy may be initiated at investigator discretion  
• Hematocrit continues to increase while on once daily dosing: study drug discontinued 
• Hematocrit does not return to normal range within 4- 8 weeks of once daily dosing: study drug 
discontinued 
• Hematocrit returns to normal range within 4 -8 weeks of initiation  of once -daily dosing: remain 
on once daily dosing 
• Hematocrit > 48% (ULN - 4%) and symptoms of polycythemia: study drug discontinued and 
subject followed until the end of study. 
 
Close Monitoring  and Stopping : Hemoglobin  
The ULN for hemoglobin is 18 g/dL ac cording to our reference laboratory. Subject s with  hem oglobin > 
18.0 g/dL  (ULN)  during the study will trigger the following close monitoring procedures.   
 
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 33 of 93 • Hemoglobin > 18 g/dL (ULN):  confirm that subject is hydrated and retest as soon as possible, 
ideally within 48 hours  
• Hemoglobin > 18 g/dL (ULN) on two consecutive assays: dose reduction (once daily dosing) will be initiated  
o Weekly monitoring of hemoglobin for subjects on onc e-daily dosing  
o Phlebotomy may be initiated at investigator discretion  
• Hemoglobin continues to increase while on once daily dosing: study drug discontinued 
• Hemoglobin does not return to normal range within 4- 8 weeks of once daily dosing: study drug 
disconti nued 
• Hemoglobin returns to normal range within 4- 8 weeks of initiation of once -daily dosing: remain 
on once daily dosing 
 
 Monitoring for Hepatotoxicity and Stopping Criteria  for Hepatoxicity  
Each subject ’s baseline values of ALT, AST, ALP,  and TB  (by at le ast two samples obtained at least 2 
weeks apart)  will be established during screening. After the baseline values are established during 
screening, the DILI algorithm provided in Appendix  B and Appendix  C will be used for monitoring 
liver safety AEs and drug -induced liver injury (DILI).  
 Testosterone Monitoring and Stopping Criteria  
Testosterone will be measured periodically during the study to ensure subject s do not experience 
elevated T levels.  An independent safety physician, not a part of the study team, will be assigned to monitor testosterone levels and implement appropriate protocol directed procedures throughout the study.  
Close monitoring and stopping criteria for T are provided below:  
Stopping Criteria  for T  
If a subject  experiences  a T measurement in excess of 1500 ng/dL  while on treatment, a repeat of the T 
assay should be scheduled within 48 hours.xxxii  If T concentrations in excess of 1500 ng/dL are repeated 
in the  subject , the subject  will be placed on a r educed dose (LPCN 1144 or placebo) of once daily 
administration (one capsule, once daily) .    
If T concentrations in excess of 1500 ng/dL are repeated  in a subject  at a once daily dose, study drug 
must be discontinued, but the subject should be followed in the cl inical trial.  If the T concentration 
remains above 1500 ng/dL at exit, proceed with weekly T assays until T concentrations have returned to 
below 1500 ng/dL . 
 Common Terminology Criteria for Adverse Event Stopping Criteria  
The trial will be stopped based on the following stopping c riteria : 
a. If one subject  experience  a Grade V CTCAE (Common Terminology Criteria for 
Adverse Event)  related to study drug,  
b. or two subject s experience the same Grade IV CTCAE  related to study drug,  
c. or three subject s experienced the same Grade III CTCAE  related to study drug. 
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 34 of 93 d. If four subject s experience the same Grade II CTCAE, enrollment of new subject s into 
the trial will be paused. The DSMB will assess the causality of these adverse events; if 
adverse events are deemed to be unrelated , determined  by the DSMB, then enrollment 
may resume.  
The following CTCAE criteria will be used for evaluating and discontinuing subject s in the trial: 
a. If a subject experience a Grade IV CTCAE or meets criteria listed in Appendix  A, 
discontinue the study drug.  
b. The DSMB will perform a causality assessment. The study drug may be restarted if the DSMB concludes that the AE or laboratory abnormalities were not related to study drug, 
the AE has resolved, laboratory abnormal ities have returned to baseline, and the subject  
is amenable to close clinical follow -up.  
c. If, after re -challenge, a subject  has a second serious AE or recurrent elevations of total 
bilirubin, ALT, or AST as defined in Appendix  A, study drug must be discontinued 
permanently.   
 Lost to F ollow -Up 
A participant will be considered lost to follow -up if he or she fails  to return for the scheduled visits and 
is unable to be contacted by the study site  staff .  
The following actions must be taken if a participant fails to return to the clinic for a required study visit:  
• The site will attempt to contact the participant and reschedule the missed visit and counsel the 
participant on the importance of maintaining the assigned visit schedule and ascertain if  the 
participant wishes to and/or should continue in the study. 
• Before a participant is deemed lost to follow -up, the investigator or designee will make every 
effort to regain contact with the participant (where possible, 3 telephone calls and, if necessar y, a 
certified letter to the participant’s last known mailing address or local equivalent methods). 
These contact attempts should be documented in the participant’s medical record or study file.  
• Should the participant  continue to be unreachable, he or she will be considered to have 
withdrawn from the study with a primary reason of  lost to follow -up. 
 
9 STUDY ASSESSMENTS AND PROCEDURES  
 Visit Schedule Overview  
There are four  phases of study:  
• Screening Phase for Subject req uiring testosterone/androgen washout up to 12 weeks  
  (12 weeks following intramuscular androgen injections; 4 weeks following topical or buccal 
androgens; 3 weeks following oral androgens).  
• Screening P hase for eligibility assessments (maximum 8 weeks  prior to randomization)  
• Randomization Phase (one visit)  
• Treatment Phase ( eight visits)  
• Follow -up (one visit)  
The visits are described in the following sections.  Note that given that all the procedures note d for a 
visit may not be available at a given clinic, visit procedures may take place over several days, at different sites.  
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 35 of 93  
 Screening Phase for Subject requiring testosterone/androgen washout  
Subjects who are on medications that require washout for eligi bility prior to screening will complete the 
following procedures:  
• Obtain informed consent.  
• Baseline medical history and chart review to determine basic eligibility based on history.  
• Review current and past medication history to determine eligibility or req uire discontinuation. 
 
 Screening V isits and Baseline D ata C ollection  
Investigators will review subject  charts for their eligibility and complete standard of care tests and 
procedures for NASH and invite to undergo screening. All screening related activities will be conducted 
after subject  reads and signs study specific informed consent.  
Screening and baseline data collection procedures will include questionnaires, physical examination, 
determination  of the subject ’s hypogonadal status  based on T  levels below the normal range , 
measurement of serum glucose, routine liver tests, and urine an alysis. Prior therapy for NASH, lipid 
lowering, diabetes , hypertension medication will be reviewed, and subject s will be asked to stop any 
specific or contraindicated / prohibited treatments , if medically acceptable.  Subject s taking diabetic, 
lipid lowering, hypertensive medication will be reviewed and only enrolled if they are on stable 
medication for at least 3 months prior to screening and encouraged to maintain stable medication after 
randomization. Sliding scale insulin is allowable, so long as the pa rameters of the scale do not change.  
Subject s who are currently taking an androgen (wash out period described earlier) or vitamin E  > 100 
IU/day  (at least 4 weeks washout period prior to randomization during screening)  will be washed out.  
Subject  charts w ill be reviewed for historical information.  
All subject s screening outcomes will be captured in the source documents ; further all subject s should 
either be screen pass to continue , or a screen fail.  
 
9.1.2.1 Screening period will consist of multiple visits with confirmation of subject eligibility through progression.  
Subject s who appear to qualify based on physician chart review and invited to participate will complete 
the following procedures  as provided in Schedule of Activities (SOA) : 
Initial assessments:  
• Obtain I nformed C onsent  (unless main Informed Consent was given at Washout) . 
• Baseline medical history and chart review to determine basic eligibility based on history.  
• Obtain demographic information, anthropomorphic measur ements . 
• Review current and past medication history to determine eligibility or require discontinuation. 
• Collect adverse events information (solicited or spontaneously reported). Subjects should be specifically queried if they have experienced any untoward signs or symptoms that would reflect cardiovascular or hypertensive adverse events, such as changes to medication due to elevations in blood pressure.  
• Conduct a detailed physical examination.  
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 36 of 93 • Assess if any Fibr oscan data collected within 30 days of screening  
If subject appears to qualify based on initial assessments:  
• Perform Urinalysis  
• Perform drug and alcohol screen.  
• Fibroscan  if needed  for subjects  but only evaluated for eligibility on subjects without a 
qualifying historical biopsy within 4 months of Screening.  
• Obtain data on historical liver biopsy if available within 4 months from Screening and 
submit to the central reader for review . 
• Collect blood samples  for clinical laboratory tests including Serology, Hematology panel  
including HbA1c , Metabolic panel and renal function, Hepatic panel, Testosterone Assay for 
subjects without history of previous diagnosis of hypogonadism, Hormones and related 
markers, cortisol and CBG (see S OA).   
 
9.1.2.2 Second Screening Assessment  
• Collect blo od samples for repeat of clinical laboratory tests (see S OA) to establish baseline ALT, 
AST, ALP, TB in second Screening. Second assessment  must occur not less than 14 days  after 
first Screening assessment .  If baseline value is suspected to be spurious , the test may be 
repeated.  
 
9.1.2.3 Screening V isit if no prior liver biopsy within the last 4 months  
• MRI -PDFF scans should be completed  for eligible subjects prior to  randomization. 
• If a subject is unable to undergo MRI -PDFF or DXA imaging due to health condition (e.g. 
claustrophobia, difficulty holding breath during the procedure, etc.), the missing MRI -PDFF will 
be treated as missing data, and the subject will be allowed to proceed to randomization or continue therapy upon investigator and medical monit or approval.  
• Collect adverse events information (solicited or spontaneously reported). Subjects must be specifically queried if they have experienced any untoward signs or symptoms that would reflect cardiovascular or hypertensive adverse events, such as c hanges to medication due to elevations 
in blood pressure.  
• Subject reported questionnaires will be completed and includes A lcohol  (Appendix  D), 
Functional Activity  (Appendix  E), I-PSS ( Appendix  F), HR -QOL  (Appendix  G), PGI -S 
(Appendix  H), Chronic Liver Disease Questionnaire (CLDQ) (Appendix  J) and Sexual Desire 
and Distress ( Appendix  K) questionnaires .  Details are provided in section 7.3.1. 
• Liver biopsy. 
• Continued eligibility with respect to medications taken or new medical history developed or reported.  
 
9.1.2.4 Imaging Screening Visit  
• Imaging study: dual -energy absorptiometry (DXA) scan for whole body lean mass, appendicular 
lean mass, fat mass, and bone mineral density (femoral and lumbar) .  
• If not completed in an earlier visit, complete subject reported questionnaires  (see SOA)  (See 
Appendix  D-K).  Details are provided in section 7.3.1. 
• Continued eligibility with respect to medications taken or new medical history developed or 
reported  
• Perform gait speed and hand grip assessments , as applicable  
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 37 of 93  
 Randomization V isit (RZ ; Day1)  
• Subject s who meet all the inclusion criteria and do not meet any exclusion criteria will be 
allowed to participate in the study. 
• Screening  medical history and chart review to determine basic eligibility based on h istory.  
• Review current and past medication history to determine eligibility or require discontinuation. 
• Collect adverse events information (solicited or spontaneously reported). Subjects must be 
specifically queried if they have experienced any untoward si gns or symptoms that would reflect 
cardiovascular or hypertensive adverse events, such as changes to medication due to elevations in blood pressure.  
• The Randomization V isit marks the Day 1 of treatment and subsequent time duration of 
treatment will be base d on the randomization day.  
• Subject ’s eligibility will be randomly assigned to receive Treatment A  (LPCN 1144 formulation)  
B (LPCN 1144 formulation  with Vitamin E ) or C ( placebo ) at 1: 1:1 randomization.  
• The random treatment assignment will consist of assigning medication bottle numbers; these 
numbers will be unique and will be specific to the particular subject  and visit it was generated 
for. Once the assignment has been generated, the subject  will be iss ued the assigned study drugs 
(in person) and instructed about starting the drugs and monitoring for adverse effects . 
• Conduct an abbreviated physical examination.  
• If not completed at Screening visit , complete subject  reported questionnaires  (see SOA) .  Details 
are provided in section 7.3.1. 
• Collect  blood samples  prior to meal and study drug administration for all  clinical laboratory tests  
including testosterone, hormones, C -reactive protein , fasting glucose and insulin, lipid panel, 
hematology panel, hepatic panel,  biomarkers , and related markers  (see S OA) for baseline 
assessment  prior to meal and study drug administration. 
• Perform baseline urinalysis.  
• An additional blood sample will be coll ected for serum and plasma banking.  Remind subject s to 
call or return to the clinic before next visit if they develop any of the signs/symptoms listed in 
the hepatoxicity assessment/stopping criteria section  8.3. 
 
 On Treatment  and Follow – up V isits  
The following visit durations are referenced from the day of randomization. Subject s will return to the 
clinic for On Treatment  visits at Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 30 , 
Week 36  and Week 3 8. 
9.1.4.1 Week 4, Week 8 , Week 12, Week 16, Week 20, Week 24 , Week 30 , Week 36 Visits   
• Review current and past medication history to determine eligibility or require discontinuation. 
• Collect adverse events information (solicited or spontaneously reported). Subjects must  be 
specifically queried if they have experienced any untoward signs or symptoms that would reflect cardiovascular or hypertensive adverse events, such as changes to medication due to elevations in blood pressure.  
• Collect dispensed investigation product ( IP) bottle and perform accountability / adherence 
checks . 
• Dispense IP at Week 4, Week 12, Week 20, and Week 30  
o Re-dispense all  returned IP . 
• Conduct physical examination  (see SOA) . 
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 38 of 93 • Complete subject reported questionnaires (see SOA).  Details are provided in section 7.3.1. 
• Perform Urinalysis  
• Obtain blood sample for clinical laboratory tests  (see S OA).  Hematology panel, HbA1c will not 
be collected at ev ery visit.  
• To ensure target T levels are achieved, subject s will have their T , hormones and related markers  
measured 3 to 5 hours post -dose; instruction for the evaluation of T levels is provided in section 
8.3.6. 
• Drug and alcohol screen (during Week 4, Week 12, and Week 24) . 
• An additional blood sample will be collected for serum and plasma banking drawn at Week 12 
and Week 36.  
• Remind subject s to call or return to the clinic before next visit if they develop any of the 
signs/symptoms listed in the hepatoxicity assessment/stopping criteria section 8.3.  
9.1.4.2 Week 12 Visit (Additional Analysis)   
• Perform anthropomorphic measurements ,
 including weight, body mass index (BMI), waist to hip 
ratio, waist circumference, triceps skin fold thickness, upper arm circumference,  
• Conduct a D etailed physical examination , except for DRE . 
• Fibroscan imaging.  
• MRI -PDFF imaging.  
• Alcohol questionnaire  AUDIT -C (Appendix  D), I-PSS ( Appendix F ), and PGI -C (Appendix I ). 
• Blood draws for all required labs except testosterone and hormones will be taken prior to meal and study drug administration. Include  HbA1c in Hematology panel.  
• Subject eats breakfast.  
• 30 minutes post meal the subject will dose.  
• 3-5 hours after dosing, testosterone and hormone samples are drawn.  
 
 
PRIMARY  ANALYSIS  
The DSMB  reviews  the planned  primary  analysis  of the MRI -PDFF outcome  measure and will be 
communicated to Sponsor  unblinded at the treatment group level but, without unblinding up to the 
individual patient level . This review  will occur  when  100%  of the MRI -PDFF measurements are 
complete . 
 The DSMB  also reviews  the overall  progress  of the trial in terms  of recruitment  and data quality
 and 
makes  a formal  recommendation to Sponsor  at the end of each scheduled  meeting  as to whether  the trial 
should continue  unmodified, continue  with protocol  modifications,  or be stopped. 
 
9.1.4.3 Week 36 Visit End of treatment  (Additional Analysis)  
• Perform anthropomorphic measurements. 
• Collect dispensed IP bottle and perform accountability / adherence checks.  
• Blood draws for all required labs except testosterone and hormones will be taken prior to meal 
and study drug administration.  
• Include HbA1c in Hematology panel  
• An additional blood sample will be collec ted for serum and plasma banking. 
• Subject eats breakfast  
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 39 of 93 • 30 minutes post meal the subject will dose.  
• 3-5 hours after dosing, testosterone and hormone samples are drawn  
• Conduct a detailed physical examination.  
• Patient reported questionnaires will be completed including Functional Activity ( Appendix  E), 
I-PSS ( Appendix  F), HR -QOL  (Appendix  G), PGI -S (Appendix  H), PGI -C (Appendix  I), 
Chronic Liver Disease Questionnaire (CLDQ) (Appendix  J) and Sexual Desire and Distress  
questionnaires  (Appendix  K). 
• Perform Gait Speed and Hand Grip assessments.  
• Imaging study: DXA scan. 
• Fibroscan imaging  
• Perform Biopsy. 
• Study exit evaluation. 
 
9.1.4.4 Follow up visit  
• Collect adverse events information (solicited or spontaneously reported).  Subjects must be 
specifically queried if they have experienced any untoward signs or symptoms that would reflect cardiovascular or hypertensive adverse events, such as changes to medication due to elevations in blood pressure.  
• Patient reported questionnaire will be completed including PGI -C (Appendix  I). 
• Perform Urinalysis  
• Collect  blood samples for clinical laboratory tests  including, lipid profile, hematology panel, 
metabolic and renal function panel, hepatic panel, Testosterone  assay, and  hormones and related 
markers  (see S OA). 
 
 
  Data and Safety  Monitoring Board (DSMB)  
An independent  Data  and Safety  Monitoring Board  (DSMB),  appointed  by Sponsor, is responsible  for 
monitoring  the accumulated  interim data as the trial progresses  to ensure  subject  safety  and to review  
efficacy.  The DSMB  is a multidisciplinary  group with a written  charge provided by Sponsor. The 
DSMB will include three or more members, at least one of whom is a hepatologist.  After  the trial 
commences,  the DSMB  will establish a charter and meet to  review  data, evaluate emerging safety 
information, or other  issues.   
 Interim data on safety  measures  requested  by the DSMB  are reviewed  at each of the scheduled
 meetings.  
Serious  adverse events  will be reviewed  by the DSMB  as they occur  with the option of a teleconference 
discussion if any DSMB  member  so requests.  
 
 Procedure Overview  
 Subject  Questionnaires  
Standardized questionnaires will be administered to subject s participating in the trial at baseline (prior to 
randomization) and during follow -up at specified intervals . The purpose of the questionnaires is to 
obtain important information r egarding alcohol intake  to assess eligibility , functional activity, health-
related quality of life, and Chronic Liver Disease Questionnaire (CLDQ)  
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 40 of 93 Alcohol questionnaires : Subject s enrolled in the treatment protocol will complete AUDIT  (Appendix  
D) and Skinner  (Appendix  D) (lifetime drinking history) questionnaires during screening, and AUDIT -
C (Appendix  D) questionnaire at interim follow -up visits . The purpose of these questionnaires is to 
ascertain that there is no significant alcohol consumption at enrollment.  
Functional A ctivity: The NHANES III Activity Questionnaire will be administered  during screening 
and after 36 weeks of treatment . The scores can be converted to METS; then the activity of NASH  
subject s can be compared to U.S. population, and the activity of NASH subject s can be compared to  
other liver disease subject s. (Appendix  E) 
I-PSS:   A questionnaire used for men who are having problems that are likely to be related to an 
enlarged prostate. ( Appendix  F) 
Health -Related Q uality of L ife (HR -QOL) : The SF -36 questionnaire will be administered during 
screening and after 36 weeks of treatment . (Appendix  G) 
Patient G lobal I mpression of S everity (PGI -S) Scale:  The Patient Global Impression of Severity 
(PGI- S) is a global index that may be used to rate the severity of a specific condition (a single -state 
scale).  It is a simple, direct, easy to use scale that is intuitively understandable to clinicians.  (Appendix  
H) 
Patient G lobal I mpression of C hange (PGI -C) Scale: This scale evaluates all aspects of subject s' 
health and assesses if there has been an improvement or decline in clinical status . (Appendix  I) 
Chronic Liver Disease Questionnaire (CLDQ) : A questionnaire on liver symptoms developed by the 
NASH CRN will be a dministered at screening and after 36 weeks of treatment.  (Appendix  J) 
Sexual D esire and Distress Questionnaire : A questionnaire used to assess level of a subject ’s distress 
due to low sexual desire. (Appendix  K) 
Alcohol questionnaires (AUDIT and Skinner; Appendix D ) and I -PSS questionnaire ( Appendix F ) are 
primarily used for eligibility assessment, therefore they need to be completed during the Screening visits 
(prior to biopsy).  
 Liver MRI -PDFF 
Sites  will schedule  subject s to have their hepatic fat fraction measured via MRI -PDFF at a local  MRI 
facility. A  local MRI facility capable of  performing the  MRI -PDFF test  will be  pre-identified by 
Sponsor/CRO  within the geographic location of  the site. Alternatively, if  the site has  a preferred  MRI 
facility, the  site can  use their preferred facility following confirmation by the Sponsor/CRO.  The MRI -
PDFF details are as follows:  
• MRI -PDFF scan will be conducted at baseline, Week 12, and Week 36. All subject s capable of 
undergoing MRI will be scheduled  to undergo an MRI scan of the liver. In case if a subject is 
unable to undergo MRI -PDFF imaging due to health condition (e.g. claustrophobia, difficulty 
holding breath during the procedure, etc.), the missing MRI -PDFF will be treated as missing 
data, and the subject will be allowed to proceed to randomization or continue the therapy upon investigator and medical monitor approval.  
• Individual subjects should have MRI -PDFF scans performed on the same MRI machine 
throughout screening and the study. 
• A central reader will assess the MRI -PDFF scans to determine the liver fat fraction.  
• All imaging sites will be provided with the 
LPCN 1144- 18-002 Manual to help with the imaging. 
• Further, all imaging sites are qualified to ensure the scan obtained is centrally readable and 
meets the criteria for a valid imaging.  
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 41 of 93 • MRI -PDFF should be performed prior to randomization but not need to be performed prior to 
biopsy, if one is required.  
 
 Fibroscan (transient elastography)  
For all sc reening and on -treatment Fibroscans, subjects must not eat food and must avoid drinking large 
volumes of water (>  400 mL, 13.5 oz) for at least 3 hours prior to the procedure. xxxvi, xxxvii 
Sites will measure subject  liver fibrosis and (if available) Controlled Attenuation Parameter (CAP) using 
Fibroscan devices.  The Fibroscan device works by measuring shear wave velocity. A 50- MHz wave is 
passed into the liver from a small transducer on the end of an ultrasound probe. The probe als o has a 
transducer that can measure the velocity of the shear wave (in meters per second) as this wave passes 
through the liver. The shear wave velocity can then be converted into liver stiffness, which is expressed 
in kilopascals.  
 Gait Speed  
Gait speed may be assessed for some subjects at select sites. Standing start, usual pace, over ground gait 
speed was assessed.  Time to complete the 10- meter  walk will be  measured using a stopwatch, and the 
tester will start the time when the participant step  over the starting line and will stop  when the 
participant completely crosses the end line . 
 Hand  Grip Strength Test  
Hand Grip Strength test may be assessed for some subjects at select sites.  
Supplies  
• Hydraulic Hand Dynamometer  
 
Definition and Purpose  
Handgri p strength is a simple and commonly used test of a person’s general strength level.  
 
Measurement  
1. Have subject sit comfortably with the shoulder adducted and neutrally rotated, with the elbow towards/against the body and flexed at 90 degrees, and the forear m and wrist in a neutral 
position.  
2. Place the hand dynamometer in the participant’s hand, and gently support the base to prevent accidental dropping and damage to the instrument. 
3. Let the participant arrange the instrument so that it fits comfortably in the hand.  Adjust the handle , if necessary , for a comfortable grip.  Make sure that the handle clip is located at the 
lower (furthest) post from the gauge .  If the handle is not in the correct position, results will be 
inaccurate.  
4. Reset the indication needle by rotating it to zero.  
5. Request th at the subject squeeze with maximum strength.  The needle will automatically record 
the highest force exerted.  Grip force should be applied smoothly, without rapid wrenching or jerking motion.  Minimal wrist extension (30 degrees or less) is permissible as maximum grip is achieved.  Wr ist extension greater than 30 degrees shall  be noted with results.  
6. Test each hand twi ce and record the handgrip strength measurement (in pounds)  for each  
measurement .  Reset the indicator needle before each and every effort.  
 
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 42 of 93 
 Liver Biopsy 
9.3.6.1  Baseline liver biopsy:   
Subject s who have  not had a liver biopsy within  4 months  of Screening  or whose  previous  liver biopsy is 
not available for review  or whose  previous  liver biopsy is of inadequate  quality  must  have  a liver biopsy 
prior  to randomization. The biopsy should be done  once  the subject  has been  found to be  eligible  with 
respect  to all other  criteria.  Biopsy slides  should  be of adequate size, preferably  1.5 cm or more  and of 
adequate quality  for interpretation.  The subject  must  have  not been  using  anti-NASH drugs  in the 3 
months  prior  to baseline biopsy, and the subject  must  have  histologic  evidence of definite  or possible  
NASH and F1-F3  fibrosis as described  in section  3.1 of this protocol. 
In the case of a biopsy done  previously as standard  of care,  the NASH CRN  study physician  should 
check  if tissue  blocks  and/or  additional  slides  can be obtained from  the original  biopsy. If the liver 
biopsy is completed  as part of screening  for this trial, the liver tissue  will be prepared  for light 
microscopy and stains  will include  hematoxylin  and eosin, Masson’s trichrome  and iron stain; 
additionally, a piece of liver tissue  will be snap frozen and  stored  at -70 degrees  C and set aside for 
banking. 
In the event that a subject  has two liver biopsies with 4 months of Screening , and both are of sufficient 
quality, the higher biopsy scoring will be used for baseline.  
9.3.6.2 Follow -up Liver B iopsy:  
A follow -up liver biopsy will be obtained at the Week 36 Visit. Guidelines for obtaining the biopsy 
specimen are provided in the LPCN 1144- 18-002 Liver Biopsy Procedure and NAFLD/NASH 
Histology Scoring System Manual; a 16- gauge  needle is  preferred,  and the specimen should be at least 
1.5 cm in length. The slides should be of adequate size ( preferably 1.5 cm or more) and adequate quality 
for interpretation. The follow -up liver biopsy should be taken from the same lobe of the liver as the 
baseline/historical biopsy. The liver tissue will be  prepared for light microscopy and stains will include 
hematoxylin and eosin, Masson’s  trichrome and iron s tain; additionally, a piece of liver tissue will be 
snap frozen and stored at - 70 degrees C and set aside for banking.  
9.3.6.3 Overview  of Scoring  of Liver Biopsies  
The tissue  will be examined  by light microscopy  and scored  based  upon the NAS  and NASH CRN 
fibrosis score . The scoring system is detailed in the LPCN 1144- 18-002 Liver Biopsy Procedure 
Manual.  
The component  scores  will be used to determine eligibility  as well as primary  histologic  outcome  
measure defined  elsewhere in this protocol. Baseline and follow -up liver biopsies  will be scored  by 
central  review  of the slides . The scores  obtained  centrally  will be used for inclusion criteria, and data 
analysis.  
 Medical and Medication History  
The subject ’s medical history (key events) during the past 5 years will be obtained and recorded on the 
Medical History Electronic Case Report Form (eCRF). Any new information / changes shall  be 
documented during the study. If a clinical event concerns a chronic disorder, which means it started in 
the past and it is still present at the screening visit, it shall also be recorded on the Medical History 
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 43 of 93 eCRF.  
All subject s must be instructed to use adequate contraception for the duration of the study, acceptable 
methods of birth control for subject s and their partners include the following methods: abstinence, 
barrier methods, hormonal contraception, intrauterine devices, fallopian tube occlusion devices, and 
sterilization either of the male or female partner .  
Medication use (prescription or over t he counter , including vitamins and herbal supplements)  from 3 
months prior to study drug administration through the end of the study will be recorded i n the eCRF .  If 
a subject  reports taking any over -the-counter or prescription medications, vitamins and/or herbal 
supplement or if administration becomes necessary from 3 months prior to study drug administration through the end of the study, the name of the medication, dosage information including dose , route, 
frequency, date(s) of administration including s tart and end dates, and reason for use must be recorded.   
Subject s participating in the trial must be naive to androgen replacement  and vitamin E  or has 
discontinued current therapy and completed an adequate washout. Recommended adequate washout is up to 12 weeks following long acting intramuscular androgen injections; 4 weeks following topical or buccal androgens; 3 weeks following oral androgens ; 4 weeks following oral vitamin E  > 100 IU/day, 
or, in the judgement of the Medical Monitor , the subject  has h ad an adequate washout window to be 
eligible . 
Subject s with a chronic condition requiring medication must:  
• Be under stable treatment , with the same medication and dosage for at least 3 months prior to 
first dosing.  
• Have no expected change to medication pl anned throughout the study. Sliding scale insulin 
dosing is acceptable.  
• The subject ’s medication should have no interaction with the pharmacokinetics of the study 
drug or the bioanalytical methods . 
 Physical Examinatio n 
Physical examinations will be performed at visits throughout the study noted in the SOA. A detailed physical includes measurement of height, weight, waist, and hips; vital signs  (temperature (single measurement) , respiratory rate  (single measurement), a prostate digital rectal examina tion (DRE), and 
clinic BP  (triplicate measurement)  and pulse rate (triplicate measurement) ; triceps skin fold thickness, 
mid upper arm circumference; examination for scleral icterus and pedal edema and auscultation of the heart and lungs; general physical findings (hepatosplenomegaly, peripheral manifestations of liver disease, ascites, wasting, fetor).  An abbreviated physical  includes measurement of height, weight, waist, 
and hips; vital signs (temperature (single measurement) , respiratory rate  (single mea surement), and 
clinic BP  (triplicate measurement)  and pulse rate (triplicate measurement) ; examination for scleral 
icterus and pedal edema and auscultation of heart and lungs . Any changes during the study will be 
documented. Subject 's height and weight wil l be used to calculate BMI .  
9.3.9 Clinic BP and Pulse Rate (PR) Measurement Methodology:  
Clinic BP and PR will be measured at visits throughout the study as part of physical examination.  An 
appropriately sized cuff for the size of the subject’s arm circu mference must be utilized to minimize 
inaccurate readings.  No smoking or exercise for at least 30 minutes before a blood pressure 
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 44 of 93 measurement.  Subjects must sit in a chair with a back support and the arm supported at heart level with 
feet flat on the flo or. If necessary, t he subject should void prior to the measurement.  Blood pressure and 
PR will be measured in triplicate over a minimum of approximately 10 minutes after the subject has 
rested in a sitting position for at least 10 minutes. The three measurements will each be recorded in the 
CRF and a mean value for that visit will be calculated.  
 Clinical Labora tory Tests  
For all subject s, blood and urine s amples will be taken as directed in the SOA . Sites will collect s amples 
for serum chemistry tests  in the morning prior to meals .  Specific stopping criteria for hematocrit, 
hemoglobin, prostate specific antigen, testosterone, and liver enzymes are provided in section 8.3.  In 
addition, subject s will be monitored for other clinical laboratory tests provided in the SOA; i f a subject  
develops clinically significant laboratory abnormality/ies for any other laboratory test during the study, 
closely monitor the subject  and perform the laboratory test (s) weekly , until the laboratory 
abnormality/ies  are normalized.  
Table 1:  Listing of Clinical Laboratory Tests for all Subjects  
 
Hematology /Coagulation  Clinical Chemistry  Hormones  
Hematocrit  
Hemoglobin  
Hemoglobin A1c    
  (HBA1C)  
Complete Blood Count  
  (CBC)  
Prothrombin time (PT)  
International normalized ratio  
  (INR) Albumin  
Alkaline phosphatase ( ALP ) 
Bile acid  
Bilirubin  
Blood urea nitrogen ( BUN ) 
Cortisol and C ortisol Binding Globulin  
C-reactive protein  
Creatinine kinase  
Gamma -glutamyltransferase ( GGT ) 
Glucose  
Prolactin  
Prostate Specific Antigen ( PSA) 
Serum glutamic -pyruvic transaminase 
(SGPT/ALT)  
Serum glutamic -oxaloacetic transaminase 
(SGOT/AST)  
 DHT  
FSH 
Insulin  
LH 
Prolactin  
Prostate specific  antigen  
SHBG  
Testosterone  
TSH  
 
Lipids  
Free fatty acid  
HDL cholesterol  
LDL cholesterol  
Total cholesterol  
Triglycerides  
VLDL cholesterol  
Clinical laboratory testing must be performed by appropriately credentialed laboratories. Certified central laboratories will process and provide results for the tests conducted at screening and throughout the study. The certified study laboratories for sa mple shipment and contact information will be provided 
in lab manual. 
 Screens for Drugs of Abuse and Alcohol  
Sites will collect urine samples to  screen for drugs of abuse and alcohol at s creening. The panel for 
drugs of abuse will minimally include opiates , barbiturates, amphetamines, cocaine, and 
benzodiazepines. A nalyses will be performed by a certified laboratory . 
 Prostate -Specific Antigen (PSA)  and Digital Rectal Exam  
Sites will collect samples for PSA at screening.  A digital rectal exam (DRE) is also  part of screening 
procedures.  T he PSA samples must be collected prior to the DRE. 
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 45 of 93 
 Testing for Adrenal Insufficiency  
If, at any time during the study, a subject  experiences  signs and symptoms of adrenal insufficiency (AI) 
(i.e. unexplained extreme fatigue, abdominal pain, nausea, vomiting, unexplained hypoglycemia, 
hyponatremia with hyperkalemia), or, if the cortisol is < 18 mcg/dL at baseline or end of study, the  
subject  will have a cosyntropin stim test as follows:  
The current standard for diagnosing adrenal insufficiency is cosyntropin stimulation testing using the standard high- dose of cosyntropin (250 mcg). An adequate response is defined by a peak cortisol level 
of at l east 18 mcg/dL (497 nmol/L) after 30 or 60 minutes of cosyntropin administration.  
Subject s must  be educated about the signs or symptoms of adrenal insufficiency (such as -- fatigue, 
muscle weakness, low appetite,  weight loss, and belly pain); and cortisol  will be drawn at any time 
during the study if AI is suspected, followed by a cosyntropin stim test as needed. If a subject develops AI or has an abnormal stimulation testing at the end of the study, they will be followed until normalization of the results  or return to baseline .  
 Safety issues  
Safety issues can be divided into (a) safety concerns relating to the therapeutic interventions, (b)  safety 
concerns related to liver biopsy, and ( c) issues related to  the central specimen repository.  
 Safety C oncerns R elated to the T herapeutic A gents  
The following paragraphs discuss the important potential adverse effects and the proposed safeguards to minimize the risks involved.  
9.4.1.1 Safety Issues Related to LPCN 1144 
 LPCN 1144 was extensively studied in non- clinical and  clinical studies. In clinical studies a twice daily 
dose 225 mg of TU  (450 mg total daily dose) was exposed in multiple studies for up to one -year 
duration.  In clinical studies, t he most frequently occurring adverse events in LPCN 1144 treated 
subjects were headache ( 4.0%  of subjects ), upper respiratory tract infection (3.0% of subjects ), weight 
increased (2.3% of subjects ), and nasopharyngitis (1.7%  of subjects ). 
LPCN 1144 must not be used in any of the following subject s:  
• Men with carcinoma of the breast or known or suspected carcinoma of the prostate.  
• Women who are, or who may become pregnant, or who are breastfeeding. LPCN 1144 may 
cause fetal harm when administered to a pregnant woman. LPCN 1144 may cause serious 
adverse reactions in nursing infants. If a pregnant woman is exposed to testosterone, she must be apprised of the potential hazard to the fetus. 
 LPCN 1144 capsules shall not be used in subject s with known hypersensiti vity to any of its ingredients . 
9.4.1.2 Safety  Issues Related  to Placebo  
The ingredients in the placebo capsules are commonly used compendial excipients.  Subject s with 
known hypersensitivity to any of the ingredients shall not be included in the trial.  Participa nts will
 be 
seen frequently  during the study period  for assessment  of symptoms , clinical laboratory tests, and reporting 
of adverse events . 
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 46 of 93 9.4.1.3 Safety Issues R elated to Vitamin E  (d-alpha tocopherol ) 
Vitamin  E at 800 IU daily  dose has no significant  toxicity  in adults.xxxiii xxxiv, Although use of 
antioxidants  may improve  insulin  resistance and thereby  may reduce  the incidence  of new-onset  
diabetes,  it is safe to assume  that the magnitude  of risk of new-onset  diabetes  mellitus  in subject s 
randomized  to vitamin  E is the same as placebo .  
9.4.1.4 Management  of Adverse  Effects  Attributed  to Study Medication  
During the trial, if a participant  develops  side effects  thought  to be due to the study medication  and 
requires  cessation  of study medication,  the medication  will be stopped for 4 weeks.  If the side effects  
disappear,  an attempt  will be made to reintroduce  the study medication  after 4 weeks.  If the symptoms  
reappear,  study medication  will be once  again  stopped, and the subject  will no longer  receive the study 
medication,  but will be followed  in the study according  to the protocol, in keeping  with the “intention -to-
treat” paradigm.  
 Safety  Issues Related  to Liver Biopsy  
Subject s will have  up to two liver biopsies  for research  purposes  during their participation  in this 
protocol. About  20% of people  who have  a liver biopsy have  some  degree of pain over the liver that 
may last a few minutes  up to several  hours. This occasionally  requires  pain medication  and usually  
disappears  completely  within  a day or two. A rare complication  of liver biopsy is severe bleeding such 
that a blood transfusion or even  radiological/surgical interventions  are required  to stop the bleeding (less 
than 1 in 1,000). Very  rarely  (less than 1 in 10,000 reported  cases)  death  has occurred  from  bleeding  
after a biopsy. We intend  to minimize  the risks  associated  with liver biopsy (a) by requiring that each of 
the physicians  who will obtain liver biopsies  in the NASH CRN  be very experienced in  safely  obtaining 
the liver biopsy specimens,  (b) by not enrolling subject s with cirrhosis or  subject s with coagulopathy, 
and assuring that subject s do no develop coagulopathy during the course of the trial, (c) by adhering to 
the good clinical  practice  in performing  the liver biopsy, (d) by assuring  that an attending hepatologist  or 
radiologist  directly  supervises  if a physician trainee  is performing  the procedure, and (e) by considering a 
trans jugular  liver biopsy in morbidly obese  subject s in whom  a percutaneous, mid-axillary  approach  may 
not be feasible.  
 Safety Issues Related to Specimen Repository  
It is anticipated that serum, plasma, DNA, and liver tissue from the participants will be stored for future 
studies related to NASH and  possibly other liver/metabolic diseases. These samples will be stored in a 
central repository.  
 Adverse Events and Serious A dverse E vents  
The investigator will monitor each subject  for clinical and laboratory evidence of AEs on a routine basis 
throughout the study. The investigator will assess and record any AE in detail including the date of onset, event diagnosis (if known) or sign/symptom, severity, time course, duration, outcome, relationship of the AE to study drug, and any action(s) taken. For serious AEs not considered "related" to study drug, the investigator will provide an “Other” cause of the event. For AEs to be considered intermittent, the events must be of similar nature and severity. Adverse events, whether in response to a query, observed by site personnel, or reported spontaneously by the subject  will be recorded. All AEs 
will be followed to a satisfactory resolution. 
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 47 of 93 
 Definition of Adverse Events (AE)  
Adverse event means any untoward medical occurrence associated with the use of an intervent ion in 
humans, whether or not considered intervention- related (21 CFR 312.32 (a)).  
An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally 
associated with the use of a medicinal (investigational) product, whether or not the event is considered causally related to the use of the product. 
Such an event can result from use of the drug as stipulated in the protocol or labeling, as well as from 
accidental or intentional overdose, drug abuse, or drug withdrawal. Any worsening of a pre- existing 
condition or illness is considered an AE. Worsening in severity of a reported AE will be reported as a new AE. Laboratory abnormalities and changes in vital signs are considered to be AEs only if they result in discontinuation from the study, necessitate therapeutic medical intervention, and/or if the investigator considers them to be AEs. 
 Definition of Serious Adverse Events (SAE)  
If an AE meets any of the following criteria, it is to be reported to the Sponsor /PI as an SAE within 24 
hours of the site being made aware of the SAE:  
Event  Description of Event  
Death of Subject   An event that results in the death of a subject . 
Life-Threatening  An event that, in the opinion of the investigator, would  have resulted in 
immediate fatality if medical intervention  had not been taken. This does 
not include an event that  would have been fatal if it had occurred in a 
more severe form.  
 
Hospitalization or  
Prolongation of  
Hospitalization   An event that results in an  admission to the hospital for  any length of 
time or prolongs the subject 's hospital stay. This does not include an 
emergency room visit or  admission to an outpatient facility.  
 
Congenital Anomaly  An anomaly detected at or after birth, or any anomaly that  results in fetal 
loss in the female partner of a study subject . 
 
Persistent or 
Significant  
Disability/Incapacity  An event that results in a condition that substantially  interferes with the 
activities of daily living of a study  subject . Disabi lity is not intended to 
include experiences  of relatively minor medical significance such as 
headache,  nausea, vomiting, diarrhea, influenza, and accidental  trauma 
(e.g., sprained ankle).  
 
Important Medical 
Event Requiring Medical or Surgical Intervention to Prevent Serious 
Outcome  An important medical event that may not be immediately life -
threatening or result in death or hospitalization, but based on medical judgment may jeopardize the subject  and may require medical or 
surgical intervention to prevent any of the outcomes listed a bove (i.e., 
death of subject , life-threatening, hospitalization, prolongation of 
hospitalization, congenital anomaly, or persistent or significant 
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 48 of 93 disability/incapacity). Examples of such events include allergic 
bronchospasm requiring intensive treatment i n an emergency room or at 
home, blood dyscrasias or convulsions that do not result in inpatient 
hospitalization, or the development of drug dependency or drug abuse.  
 
For SAEs with the outcome of death, the date and cause of death will be recorded on the appropriate 
eCRF.  
 Classification of an Adverse E vent 
9.5.3.1 Severity of Event  
For adverse events ( AEs) not included in the protocol defined grading CTCAE system, the following 
guidelines will be used to describe severity.  
• Mild – Events require minimal or no tre atment and do not interfere with the participant’s daily 
activities.   
• Moderate – Events result in a low level of inconvenience or concern with the therapeutic 
measures. Moderate events may cause some interference with functioning.  
• Severe – Events interrupt  a participant’s usual daily activity and may require systemic drug 
therapy or other treatment. Severe events are usually potentially life -threatening or 
incapacitating.  Of note, the term  “severe” does not necessarily equate to “serious”.]  
 
9.5.3.2 Relationship to Study Intervention  
All adverse events ( AEs) must have their relationship to study intervention assessed by the clinician 
who examines and evaluates the participant based on temporal relationship and his/her clinical 
judgment. The degree of certainty about causality will be graded using the categories below. In a 
clinical trial, the study product must always be suspect.  
• Related  – The AE is known to occur with the study intervention, there is a reasonable possibility 
that the study interventi on caused the AE, or there is a temporal relationship between the study 
intervention and event. Reasonable possibility means that there is evidence to suggest a causal 
relationship between the study intervention and the AE.  
• Not Related  – There is not a reasonable possibility that the administration of the study 
intervention caused the event, there is no temporal relationship between the study intervention and event onset, or an alternate etiology has been established.  
9.5.3.3 Expectedness  
The investigator will be responsible for determining whether an adverse event ( AE) is expected or 
unexpected.  An AE will be considered unexpected if the nature, severity, or frequency of the event is not consistent with the risk information previously des cribed for the study intervention. 
 Time Period and Frequency for Event Assessment and Follow -Up 
All AEs in the subject  and pregnancies that occur in subject ’s partner reported from the time of 
informed consent until completion of the last visit after the last dose of study drug will be collected, whether solicited or spontaneously reported by the subject . 
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 49 of 93 The occurrence of an adverse event ( AE) or serious adv erse event ( SAE ) may come to the attention of 
study personnel during study visits and interviews of a study participant presenting for medical care, or 
upon review by a study monitor. 
All AEs including local and systemic reactions not meeting the criteria for SAEs will be captured on the 
appropriate  case report form  (CRF ). Information to be collected includes event description, time of 
onset, clinician’s assessment of severity, relationship to study product (assessed only by those with the 
training and authority to make a diagnosis), and time of resolution/stabilization of the event. All AEs occurring while on study must be documented appropriately regardless of relationship. All AEs will be followed to adequate resolution.  
Any medical condition that is pres ent at the time that the participant is screened will be considered as 
baseline and not reported as an AE. However, if the study participant’s condition deteriorates at any time during the study, it will be recorded as an AE.  
Changes in the severity of an AE will be documented to allow an assessment of the duration of the event 
at each level of severity to be performed. AEs characterized as intermittent require documentation of onset and duration of each episode.  
Site staff will record all reportable event s with start dates occurring any time after informed consent is 
obtained until the last follow up visit. If the site becomes aware of a related SAE at any time after completion of the study, it must be reported.  Events will be followed for outcome informa tion until 
resolution or stabilization.  
 Adverse Event Reporting 
To report an SAE, complete the SAE eCRF in the EDC system for the study. When the form is completed, Medpace Clinical Safety personnel will be notified electronically and will retrieve the for m. 
If the event meets serious criteria and it is not possible to access the EDC system, send an email to Medpace Clinical Safety at medpace- safetynotification@medpace.com or call the Medpace SAE hotline 
(phone number listed below), and fax/email the comple ted paper back -up SAE form to Medpace 
(contact information listed below) within 24 hours of awareness. When the EDC system becomes available, the SAE information must be entered within 24 hours of the system becoming available. Incoming reports are reviewe d during normal business hours.  
Safety Contact Information:  
Medpace Clinical Safety Medpace SAE hotline – USA: Telephone: +1 -800-730-5779, dial 3 or +1 -513-
579-9911, dial 3 Facsimile: +1- 866-336-5320 or +1- 513-579-0444 e -mail: medpace -
safetynotification@ medpace.com  
 Monitoring for Adverse  Events  
Summary  data on adverse events  will be monitored by the DSMB  as needed. These summaries  will 
include  analyses  comparing  rates  of adverse events  by treatment group, by clinic,  or in other  subgroups  
requested  by the DSMB.  Where  applicable,  signs  and symptoms  associated  with the adverse event  will 
be graded  as to severity  by the clinical  site staff as mild,  moderate,  or severe  using the Common  
Terminology Criteria  for Adverse  Events.  
After  each meeting,  the DSMB  will issue  a written  summary  of its review  of the study data,  including 
adverse events,  for transmission  to the IRBs  at each of the study centers.  Analyses  or listings  of adverse  
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 50 of 93 events  will not be provided to the IRBs;  however,  adverse events  involving  unanticipated  problems  
involving risks  to participants,  or breaches  of protocol  which  might entail  risk to participants  must  be 
reported  to local  IRBs  as soon as possible  after they are discovered.  Each  participating  center  is 
responsible  for ensuring that all local  IRB requirements  for reporting adverse events  are met. 
 Reporting of Pregnancy  
The study only enrolls male participants who will be required to use adequate contraception throughout 
the duration of the study.  
However, if the subject ’s partner becomes pregnant while the subject  is in the study, it must  be reported 
to the site as soon as possible. The study site staff will fill a Pregnancy in P artner form and the Sponsor will be notified within 24 
hours.  
10 STATISTICAL CONSIDERATIONS   
A formal  Statistical Analysis Plan  (SAP) will be completed and incorporated prior to database lock and 
unblinding of the study data. The SAP will govern the statistical analysis for the study. The following 
sections only outlines key statistical points.  
 Outcomes 
Primary Outcome Measure:  
Change in hepatic fat fraction based on MRI -PDFF measurements  in LPCN 1144 treated subject s after 
12 weeks of treatment . 
 Key Secondary  Outcome Measures:  
Change in NASH activity or change in fibrosis.  Changes in NASH activity will be evaluated  via a 
standardized scoring of liver biopsies at bas eline and after 36 weeks of treatment in LPCN 1144 treated 
subject s, while changes in fibrosis will be evaluated via NASH CRN fibrosis score  of liver biopsies at 
baseline and after 36 weeks of treatment . 
Change in NASH activity is derived  from changes  from  baseline to the end of treatment  in NAS.  The 
NAS  ranges  from  0 to 8 (highest  activity)  and is calculated  as the sum of three
 components  of the 
standardized  histologic  feature scoring system  for liver biopsies:  
NAS   =  Steatosis  score (0-3) + 
Lobular  inflammation  score  (0-3) +  
Hepatocyte ballooning score  (0-2) 
 The analysis of the Key S econdary O utcome M easure will include both improvement in NAS  and 
fibrosis , and numerical change in NAS  and fibrosis .  The analysis for improvement of NAS will only 
include subjects with a baseline hepatocyte ballooning score of 1 or 2. The definition  of improvement  of 
NAS after treatment as the key secondary  outcome  measure requires  the following three conditions:  
• No worsening of the NASH CRN scoring system . 
• Improvement  by at least 1 point  in the hepatocyte  ballooning feature  score.  
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 51 of 93 • Either:     
1. Improvement  in NAS  by 2 or more  points  spread  across  at least two of the NAS  components, 
OR 
2. Post-treatment  NAS  is 3 points  or less. 
Similarly, improvement in fibrosis will be defined as improvement in liver fibrosis greater than or equal 
to one stage using the NASH CRN fibrosis score  with n o worsening of ballooning, inflammation, or 
steatosis.  
 
Other Secondary Outcome Measures:  
• Relati ve change in hepatic fat fraction based on MRI -PDFF measurements in LPCN 1144 treated 
subjects after 12 weeks of treatment.   
• Change in hepatic fat fraction based on MRI -PDFF measurements in LPCN 1144 treated subjects 
after 36 weeks of treatment.   
• Relativ e change in hepatic fat fraction based on MRI -PDFF measurements in LPCN 1144 treated 
subjects after 36 weeks of treatment.   
• NAFDL resolution of subjects who at baseline is at least 5% of hepatic fat fraction with a decrease 
to less than 5% at end of study.  
• Resolution of NASH on overall histopathological reading.  Resolution of NASH is defined as NAS 
score of 0 –1 for inflammation, 0 for ballooning, and any value for steatosis. 
• Change in individual NAS component scores (inflammation, ballooning, steatosis) in LPCN 1144 
treated subjects after 36 weeks of treatment.  
• Resolution of NASH on overall histopathological reading and no worsening of liver fibrosis on 
NASH CRN fibrosis score.  
• Improvement in liver fibrosis greater than or equal to one stage (NASH CRN fibrosis score).  
• Change in anthropometric measurements (weight, body mass index (BMI ), waist  to hip ratio, waist 
circumference, triceps skin fold thickness, upper arm circumference ,) in LPCN 1144 treated 
subject s. 
• Change in insulin resistance (assessed by HOMA)  in LPCN 1144 treated subject s. 
• Changes in liver enzymes ( AST, ALT, A LP, GGT, TB and CK ) in LPCN 1144 treated subject s. 
• Changes in non- invasive markers of fibrosis and steatosis including cytokines, leptin, fibrosis 
markers, and lipid profile  in LPCN 1144 treated subject s. 
• Changes in lipid parameters (triglycerides, VLDL -C, HDL -C, LDL -C, and free fatty acids)  in LPCN 
1144 treated subject s. 
• Changes in Functional Activity ( Appendix  E), HR -QOL as measured by Short Form -36 (Appendix  
G), PGI -S (Appendix H), PGI -C (Appendix  I), and Chronic Liver Disease Questionnaire (CLDQ)  
(Appendix  J) and Sexual desire and distress ( Appendix  K) questionnaires  in LPCN 1144 treated 
subject s. 
• Changes in laboratory parameters (clinical chemistry, hematology and urinalysis ) in LPCN 1144 
treated subject s. 
 
 Sample Size  Determination  
This is a proof of concept  Phase 2 study aimed at evaluating the LPCN 1144 as potenti al therapeutic 
agent in the treatment and / or management of NASH. The sample size for the study was not based on 
any statistical considerations but based on similar Phase 2 studies in this therapeutic area.  
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 52 of 93 
 Populations for Analyses 
The study populations that will be used in various analysis are defined as:  
• Intention- to-Treat (ITT) Analysis Dataset (i.e., all randomized participant s) 
• Modified Intention- to-Treat  (mITT)  Analysis Dataset (e.g., participant s who took at least one 
dose of study intervention and/or have some particular amount of on- treatment data)  
• Safety Analysis Dataset: defines the subset of participant s for whom safety analyses will be 
conducted (e.g., participants who took at least one dos e of study intervention ) 
• Per-Protocol  (PP)  Analysis Dataset: defines a subset of the participant s in the full analysis (ITT) 
set who complied with the protocol sufficiently to ensure that these data would be likely to 
represent the effects of study interve ntion according to the underlying scientific model (e.g., 
participant s who took at least 80% of study intervention for 80% of the days within the 
maintenance period) . 
 
 Statistical Analyses  
 General Approach  
A p-value of 0.05 will be considered significant.  N o adjustments  for the additional  analysis or multiple  
comparisons  will be applied ; however, any significant  findings  must  be interpreted  taking into account  
the strength of the finding and its biologic  plausibility.  
Continuous data will be summarized using count, mean, median, standard deviation (SD), minimum, 
and maximum.  For continuous data specified to be analyzed using parametric procedures, non -
parametric procedures will be used if the parametric procedure is felt to be inappropriate.  
Potential treatment- by-site interactions in terms of the baseline data and the primary efficacy and safety 
endpoints will be investigated by visual inspection of the data by site. Visual evidence of extreme 
imbalance by site will be  handled in subsequent models by including site as a term in the model.  
Summary tables, listings, and figures, and statistical analyses will be done using SAS version 9.1 or higher or R, version 2.0 or higher.  
Unless otherwise noted, efficacy analyses wil l be conducted for the ITT. Safety analyses will be 
conducted for the Safety population only. 
When an analysis calls for statistical modeling of the outcome variable using potential confounders as 
well as the treatment effect, the analysis will begin with the full model. If a potential confounder is not statistically significant in the full model, it will be dropped, and the analysis repeated using a reduced 
model. 
 Procedures for Missing Data  
Missing data will be reported as such. Raw data will be subjected  to a statistical screen for outliers using 
commonly accepted procedures.  
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 53 of 93 
 Efficacy Analyses  
10.4.3.1 Primary Efficacy Analyses  
The primary outcome measure will be analyzed using an analysis of covariance (ANCOVA) model with 
treatment group as a factor and baseline hepatic fat fraction (%) based on MRI -PDFF measurements as a 
covariate. The LPCN 1144 dose groups will be compared to each other and compared to placebo independently using linear contrasts. 
The analysis of the primary outcome measure will be performed using the ITT population. The mITT 
and PP populations will be used as sensitivity analyses.   
10.4.3.2 Key Secondary Efficacy Anal yses 
Change from baseline in key secondary outcome measure s will be analyzed both as a binary outcome  
(improved  vs. not improved)  and also
 in terms  of the numerical  change  in the outcome s.  For the key 
secondary outcome s, improvement will be assessed based  on the criteria provided in section 10.1.  
Comparative analyses  for the key secondary outcome measure w ill be analyzed both as a binary outcome  
(improved  vs. not improved)  and also in terms  of the numerical  change  in the outcome. Binary  outcomes  
will be compared  using Fisher’s exact test . Numerical  changes  will be analyzed  by descriptively  
comparing  the between -treatment  group differences  in mean  and median  changes;  P-values  will be 
derived  from  Wilcoxon rank sum tests for comparison of the distribution of changes  in each group. If 
concerns  about  confounding arise,  logistic  regression  models  for improvement  outcomes  and linear  
regression  models  for numerical  change  outcomes  will be used to correct  for the confounding. Analyses  
for outcome measures  will generally  involve  three separate analyses,  one for each treatment  group  
comparison .  
10.4.3.3 Other Secondary Efficacy Analyses  
Other secondary efficacy outcome measures will be conducted in the similar methods of the primary and 
secondary efficacy analyses . The details of other secondary efficacy analyses will be provided in the 
SAP.  
10.4.3.4 Subgroup Analyses  
The analyses of the primary o utcome measure will be performed for the following subgroups:  
1. Subjects with baseline liver fat ≥ 5%  
2. Subjects with baseline liver fat ≥ 8%  
3. Subjects with baseline liver fat ≥ 10%  
 
The details of the subgroup analyses will be provided in the SAP. 
 Safety Analyses  
An AE that starts during a unique treatment or that already exists before the start of that unique treatment but worsens during the treatment will be considered as treatment emergent for that unique treatment.  
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 54 of 93 AEs will be reported on a per -subject  basis, i.e., counting subject s rather than events.  This means that if 
a subject  suffers the same AE repeatedly during the applicable study period, the event will be counted 
only once for that period.  Repeated events per subject  will be summarized accord ing to the following 
rule; if a subject  suffered the same AE more than once, the event will be assigned the worst severity, the 
closest relationship to the study drug, and the earliest onset date.  Only treatment -emergent events will 
be reported.  For each  unique treatment, treatment- emergent AEs will be summarized per primary 
System Organ Class (SOC) and per Preferred Term (PT) using the MedDRA classification system.  All 
AEs, serious AEs and deaths, Serious AEs that are considered treatment -related, and A Es leading to 
premature discontinuation from the study will also be provided in data listings. 
 Cardiovascular  Risk Evaluation 
Each subject  will be evaluated for cardiovascular risk using the following algorithms.  
• Framingham Coronary Heart Disease Risk Scor e. 
• Framingham Risk Score for cardiovascular disease  
• Reynolds Risk Score.  
 A subgroup analysis will be performed showing the central tendency towards increased blood pressure  
in subjects who have a diagnosis of diabetes mellitus at baseline, in subjects who do not have a diagnosis with hypertension and are normotensive at baseline, and in subjects who have a diagnosis of 
hypertension at baseline and are controlled with medical  management.
 
 
 Other A ssessments or Analysis 
Demographics and other baseline characteristics will be summarized by analysis set.  Medical history will 
be summarized.  Major protocol deviations will be listed.  Abnormal physical examination assessments will be summarized for the Safety population. Medication use will be summarized for the Safety 
population.  Prior (prior to the start of treatment) medication use and concomitant (after the start of treatment) medication use will be summarized separately.  If the end date of a prior medication occurs after treatment starts, then the medication will be reported in both the prior and concomitant listings.  Concomitant medication use will be summarized per treatment group.  These listings will present the number and percentage of subject s for each medication.  
 
11 SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS  
 Regulatory, Ethical, and S tudy Oversight C onsiderations  
 Informed Consent Process  
Prior to the initiation of any screening or study- specific procedures, the investigator or his/her 
representative will explain the nature of the study to the subject  and answer all questions regarding this 
study. Each informed consent will be reviewed, signed and dated by the subject , the person who 
administered the informed consent, and any other signatories according to local requirements. A copy of 
each informed consent will be given to the subject  and each original will be placed in the subject 's 
medical record. An entry must also be made in the subject 's dated source documents to confirm that 
informed consent was obtained prior to any study- related procedures and that the subject  received a 
signed copy.  
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 55 of 93  
 Study Discontinuation and Closure  
This study may be temporarily suspended or prematurely terminated if there is sufficient reasonable 
cause.  Written notification, documenting the reason for study suspension or termination, will be provided by the suspending or terminating party to the investigator , IRB and regulatory authorities.  If 
the study is prematurely terminated or suspended, the  PI will promptly inform study participants, the 
Institutional Review Board ( IRB), and Sponsor  and will provide the reason(s) for the termination or 
suspens ion.  Study participants will be contacted, as applicable, and be informed of changes to study 
visit schedule. Circumstances that may warrant termination or suspension include, but are not limited to:  
 
• Determination of unexpected, significant, or unaccepta ble risk to participants  
• Demonstration of efficacy that would warrant stopping    
• Insufficient compliance to protocol requirements  
• Data that are not sufficiently complete and/or evaluable  
• Determination that the primary endpoint has been met  
• Determination o f futility  
• Administrative reasons by the Sponsor  
 Study may resume once concerns about safety, protocol compliance, and data quality are addressed , and 
satisfy the Sponsor , IRB and/or Food and Drug Administration ( FDA ). 
The investigator will provide a fina l report to the IRB following conclusion of the study and will 
forward a copy of this report to Lipocine or their representative.  
The investigator must retain any records related to the study according to local requirements. If the investigator is not able  to retain the records, he/she must notify Lipocine/CRO to arrange alternative 
archiving options.  
The end of study is defined as the date of the last subject 's last visit. If, on the date of the last subject ’s 
last visit, the subject  is experiencing an ongoing AE, the event will be followed until satisfactory 
resolution occurs . 
 Confidentiality and P rivacy  
All information concerning LPCN 1144 and Lipocine operations, such as Lipocine patent applications, 
formulas, manufacturing processes, basic scientific data, or formulation information, supplied by Lipocine and not previously published is considered confidential information. 
The information developed during the conduct of this clinical study is also considered confidential and 
will be used by Lipocine in connection with the development of LPCN 1144. This information may be disclosed as deemed necessary by Lipocine to other clinical investigat ors, other pharmaceutical 
companies, and to governmental agencies. To allow for the use of the information derived from this clinical study and to ensure complete and thorough analysis, the investigator is obligated to provide Lipocine with complete test r esults and all data developed in this study and to provide direct access to 
source data/documents for study- related monitoring, audits, IRB review, and regulatory inspection.  
This confidential information shall remain the sole property of Lipocine, shall not be disclosed to others without the written consent of Lipocine, and shall not be used except in the performance of this study. 
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 56 of 93 The investigator will maintain a confidential subject identification code list of all subject s enrolled in the 
study, including each subject 's name, subject  number, address, phone number and emergency contact 
information. This list will be maintained at the study site with other study records under adequate 
security and restricted access and will not be retrieved by Lipocine/CRO. 
 Future Use of Stored Specimens and Data  
Data collected for this study will be analyzed and stored at the central facility as indicated in the administrative study structure page. After the study is completed, the de- identified, archived data will be 
transmitted to and stored at the central facility . 
With the participant’s approval and as approved by local Institutional Review Boards ( IRBs ), de-
identified biological samples will b e stored .  
During the conduct of the study, an individual participant can choose to withdraw consent to have biological specimens stored for future research. However, withdrawal of consent with regard to bio sample  storage may not be possible after the stu dy is completed.  
When the study is completed, access to study data and/or samples will not be available to investigators or subject s. 
 Key Roles  and Study Governance 
Lipocine is the Sponsor of this study. On the initial approval date of this protocol, the administrative structure and the external organizations supporting the study are as follows: 
Sponsor: Lipocine Inc  
 675 Arapeen Drive, Suite 202 
 Salt Lake City, Utah 84108   USA 
 
 Telephone: (801) 994-7383 
 Study Director:   
 Vice Pr esident Product Development 
 Lipocine Inc  
  
   
 
 Safety Oversight 
Safety oversight will be under the direction of the Sponsor and CRO medical monitor of the study.   
 Clinical Monitoring 
A separate cli nical monitoring pla n (CMP) will be developed and used to govern the monitoring and 
quality control / conduct of the study.  
 

LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 57 of 93 
 Quality A ssurance and Q uality C ontrol  
Prior to enrolling any subject  in the study, an initiation meeting will be held with CRO personnel, the 
investigator(s), and the study coordinators/project manager(s). This meeting will include a detailed 
discussion and review of the protocol and essential documents, performance of study procedures, eCRF completion and specimen collection methods. 
The CRO monitor will monitor the study site throughout the study. Source document verification will be 
performed. A quality assurance check may be  performed to ensure that the investigator is complying 
with the protocol and regulations. In addition, after the eCRFs are submitted, a review of the data will be conducted by a representative at CRO.  
Computer logic checks will be run to identify such items as inconsistent study dates. Any necessary corrections will be made to the database via the eCRF.  
All imaging evaluations will be conducted by certified central reader . The source documents / site 
documents shall  capture the information of the personnel and facilities including qualifications. 
Rout ine hematology, serum chemistry, and urinalysis tests will be conducted using a certified clinical 
laboratory. Laboratory reference ranges will be obtained prior to the initiation of the study. A review of all laboratory results will be conducted by the CR O monitor, the investigator and other appropriate 
personnel from CRO.  
 
 Data H andling and R ecord  Keeping   
11.1.9.1 Source Documents  
Source documents are defined as original documents, data and records. These may include hospital records, clinical and office charts,  laboratory data/information, subject  questionnaires or evaluation 
checklists, pharmacy dispensing and other records, recorded data from automated instruments, microfiches, photographic negatives, microfilm or magnetic media, and/or x- rays. Source document  data 
may be transcribed onto eCRFs as required. Data collected during this study must be recorded on the appropriate source document.  
The investigator/institution will permit study -related monitoring, audits, IRB review, and regulatory 
inspection(s), providing direct access to source data documents. 
 
11.1.9.2 Case R eport Forms  
Case report forms (CRF) must be completed for each subject  who receives study medication in this 
study. These forms will be used to transmit information collected during the study to Sponsor /PI and 
regulatory authorities, as applicable. The CRF data for this study will be collected with an electronic data capture (eEDC) system (e.g., Rave, Medidata). The EDC system and the study- specific eCRFs will 
comply with Title 21 CFR Part 11. The documentation related to the validation of the EDC system is available through the system vendor, while the validation of the study- specific eCRFs will be conducted 
by the clinical research organization (CRO) and will be maintained in the Trial Master File at the  CRO.  
The investigator will document subject  data in his/her own subject  files. These subject  files will serve as 
source data for the study. All eCRF data required by this protocol will be recorded by investigative site 
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 58 of 93 personnel in the EDC system. All data entered into the eCRF will be supported by source 
documentation.  
The investigator or an authorized member of the investigator's staff will make any necessary corrections 
to the eCRF. All change information, including the date and person performing the corrections, will be available via the audit trail, which is part of the EDC system. For any correction, a reason for the alteration will be provided. The eCRFs will be reviewed periodically for completeness, legibility, and acceptability by CRO personnel ( or their representatives). The CRO (or their representatives) will also 
be allowed access to all source documents pertinent to the study in order to verify eCRF entries. The investigator will review the eCRFs for completeness and accuracy and provide his or her electronic signature and date to eCRFs as evidence thereof.  
The CRO will provide access to the EDC system for the duration of the trial through a password- protected method of internet access. Such access will be removed from investigator sites at 
the end of the site's participation in the study. Data from the EDC system will be archived on appropriate data media (e.g., CD-ROM) and provided to the investigator at that time as a durable record of the site's eCRF data. It will be possible for the investigator to make paper printouts from that media. 
 Protocol Deviations  
The investigator shall  not implement any deviation from the protocol without prior review and written 
agreement by the Sponsor and in accordance with the IRB and local regulations, except when necessary to eliminate an immediate hazard to study subject s. When a deviation from the protocol is deemed 
necessary for an individual subject , the investigator must alert the following con tact(s):  
Primary Contact  
  
 
 Alternate Contact  
 
 
 
 
Such contact must be made as soon as possible to permit a review by the Sponsor to determine the impact of the deviation on the subject  and/or the study. Any significant protocol deviations affecting 
subject  eligibility and/or safety must be reviewed and/or approved by the IRB, as applicable, prior to 
implementation . 
 Publication and Data Sharing Policy 
The data obtained is confidential property of the Sponsor, Lipocine Inc.  The Publication policy with sites will be covered under the respective clinical trial agreements. In general, no part of the trial or data can be published by sites, investigator or staff without explicit written approval of the Sponsor. 
 Conflict of I nterest  Policy  
All participating  investigators will be required to provide a financial disclosure and conflict of interest 
statement.  
 

LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 59 of 93 
 Abbreviations  
AE Adverse Event  
ANCOVA  Analysis of Covariance  
ALP  Alkaline Phosphatase  
ALT  Alanine Transaminase  
AST  Aspartate Transaminase  
CFR  Code of Federal Regulations  
CK Creatine Kinase  
CMP  Clinical Monitoring Plan  
COC  Certificate of Confidentiality  
CONSORT  Consolidated Standards of Reporting Trials  
CRF  Case Report Form  
DHHS  Department of Health and Human Services  
DILI  Drug -Induced Liver Injury  
DRE  Digital Rectal Examination  
DSMB  Data and Safety Monitoring Board  
EC Ethics Committee  
eCRF  Electronic Case Report Forms  
EOT  End of Treatment  
FDA  Food and Drug Administration  
FDAAA  Food and Drug Administration Amendments Act of 2007  
GCP  Good Clinical Practice  
GGT  Gamma -Glutamyltransferase  
GLP  Good Laboratory Practices  
HIPAA  Health Insurance Portability and Accountability Act  
HIV Human Immunodeficiency Virus  
IB Investigator’s Brochure  
ICH International Conference on Harmoni zation   
IND Investigational New Drug Application  
IRB Institutional  Review Board  
ITT Intention -To-Treat  
MedDRA  Medical Dictionary for Regulatory Activities  
MELD  Model for End -Stage Liver Disease  
mITT  Modified -Intent -To-Treat  
MOP  Manual of Procedures  
MSDS  Material Safety Data Sheet  
NAFL  Non-Alcoholic Fatty Liver  
NAFLD  Non-Alcoholic Fatty Liver Disease  
NAS  NAFLD Activity Score  
NASH  Non-Alcoholic Steatohepatitis  
NCT  National Clinical Trial  
NIH  National Institutes of Health  
NIH IC  NIH Institute or Center  
OHRP  Office for Human Research Protections  
PI Principal Investigator  
PP Per-Protocol  
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 60 of 93 QA Quality Assurance  
QC Quality Control  
SAE  Serious Adverse Event  
SAP Statistical Analysis Plan  
SMC  Safety Monitoring Committee  
SOA  Schedule of Activities  
SOC  System Organ Class  
SOP Standard Operating Procedure  
TB Total Bilirubin  
ULN  Upper Limit of Normal  
UP Unanticipated Problem  
US United States  
 
  
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 61 of 93  
12 APPENDICES  
APPENDIX  A:  Investigator’s Agreement  
APPENDIX  B:  DILI monitoring algorithm  
APPENDIX  C:  Close Observation for Potential Drug Induced Liver Injury  
APPENDIX  D:  Alcohol Questionnaire (AUDIT, AUDIT -C and Skinner)  
APPENDIX  E:  Functional Activity Questionnaire  
APPENDIX  F:  I-PSS Questionnaire  
APPENDIX  G:  HR -QOL (SF -36) Questionnaire  
APPENDIX  H:  PGI -S Questionnaire  
APPENDIX  I:  PGI -C Questionnaire  
APPENDIX  J:  Chronic Liver Disease Questionnaire (CLDQ)  
APPENDIX  K:  Sexual Desire and Distress Questionnaire  
APPENDIX L: Sponsor Signatures  
 
           
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 62 of 93 APPENDIX  A:  INVESTIGATOR'S AGREEMENT  
Study Title:  A Phase 2, Randomized Double -Blind, Placebo -Controlled, Multi -Center 
Study to Assess the Efficacy, Safety and Tolera bility of Oral LPCN 1144 
in Subject s with Nonalcoholic Steatohepatitis  (NASH)  
Study Number:  LPCN 1144 -18-002 
Final Date:  7 January 2020  
Clinical research studies sponsored by Lipocine  are subject to the Good Clinical Practices  (GCP) and 
local regulations and guidelines governing the study at the site location. In signing below , the 
investigator is  agreeing to the following:  
1. Conducting the study in accordance with the current protocol, making changes to  a 
protocol only after obtaining approval from  Lipocine , except when necessary to protect  
the safety, rights or welfare of subject s. 
2. Personally, conducting or supervising the described investigation(s).  
3. Informing all subject s, or persons used as controls, that the drugs are being used for  
investigational purposes and complying with the requirements relating to informed 
consent and institutional review board [ IRB] review and approval of the protocol and 
amendments ). 
4. Reporting adverse experie nces that occur in the course of the investigation(s) to Lipocine/ 
PI and the site director.  
5. Reading the information in the Investigator's Brochure/safety material provided, including the instructions for use and the potential risks and side effects of the  investigational 
product(s).  
6. Informing all associates, colleagues, and employees assisting in the conduct of the  study 
about their obligations in meeting the above commitments.  
7. Maintaining adequate and accurate records of the conduct of the study, making t hose 
records available for inspection by representatives of Lipocine/CRO  and/or the  
appropriate regulatory agency, and retaining all study- related documents until notification 
from Lipocine . 
8. Maintaining records demonstrating that an ethics committee review ed and  approved the 
initial clinical investigation and all amendments.  
9. Reporting promptly, all changes in the research activity and all unanticipated problems involving risks to human subject s or others, to the appropriate individuals  (e.g., 
coordinating i nvestigator, institution director) and/or directly to the ethics  committees and 
Lipocine/PI . 
10. Following the protocol and not make any changes in the research without ethics  
committee approval, except where necessary to eliminate apparent immediate hazards t o 
human subject s. 
 
I have read the protocol described above. I agree to comply with all applicable regulations and to 
conduct the study as described in the protocol.  
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 63 of 93 1. I have received and reviewed the Investigator's Brochure for LPCN 1144. 
2. I have read this protocol and agree that the study is ethical. 
3. I agree to conduct the study as outlined in the protocol and in accordance with all applicable 
regulations and guidelines. I will not deviate from the protocol without prior written approval from the sponsor or designee.  
4. I agree to maintain the confidentiality of all information received or developed in  connection 
with this protocol. 
 
   
Signature of the Investiga tor  Date  
   
   
Name of the Investigator (Printed or Typed)    
 
  
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 64 of 93 APPENDIX  B: DILI MONITORING ALGORITHM  
Treatment -Emergent  
ALT  Treatment -
Emergent  
TB Liver Symptoms  Action  
Normal baseline:  
ALT > 5x ULN  
 
Elevated baseline:  
ALT > 3x baseline  
or > 300 U/L  
(whichever occurs first)  Normal  None  Repeat ALT, AST,  
ALP, TBL, in 2 –5 
days  
 
Reduce dose (LPCN 1144 or placebo) to 
once daily administration (one capsule, 
once daily) . 
 
Follow -up for symptoms.  
Normal baseline:  
ALT > 8x ULN  
 
Elevated baseline:  
ALT > 5x baseline  
or > 400 U/L  
(whichever occurs first)  Normal  None  Interrupt study drug.  
Initiate close observation  (see Appendix 
C below and FDA guidance*) and workup for competing etiologies.  
 Study drug can be restarted only if an 
alternative etiology is ide ntified, and liver 
enzymes return to baseline.  Restart at 
reduced dose (LPCN 1144 or placebo) 
once daily administration (one capsule, 
once daily) . 
 
Normal baseline:  
ALT > 5x ULN  
 
Elevated baseline:  
ALT > 3x baseline  
or > 300 U/L  
(whichever occurs first)  TB > 2x ULN  None  Interrupt study drug.  
Initiate close observation  and workup for 
competing etiologies.  
 
Study drug can be restarted only if an 
alternative etiology is identified, and liver 
enzymes return to baseline.  Restart at 
reduced dose (LPCN 1144 or placebo) 
once daily administration (one capsule, 
once daily) . 
Normal baseline:  
ALT > 5x ULN  
 
Elevated baseline:  
ALT > 3x baseline  
or > 300 U/L  
(whichever occurs first)  Normal or elevated  Symptoms of 
clinical hepatitis -  
severe fatigue,  
nausea, vomiting,  
right upper quadrant  
pain Interrupt study drug.  
Initiate close observation  and workup for 
competing etiologies.  
 
Study drug can be restarted only if an 
alternative etiology is identified and liver 
enzymes return to baseline.  Restart at 
reduced dose (LPCN 1144 or placebo) 
once daily administration (one capsule, 
once daily) . 
Source: Adapted from Chalasani, Naga and Regev, Arie et al. Drug- Induced Liver Injury in Subjects 
with Preexisting Chronic Liver Disease in Drug Development: How to Identify and Manage? 
Gastroenterology, Volume 151, Issue 6, 1046 – 1051 
*https://www.fda.gov/downloads/Drugs/Guidance/UCM174090.pdf     
  
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 65 of 93 APPENDIX  C:  CLOSE OBSERVATION FOR POTENTIAL DRUG INDUCED 
LIVER INJURY  
Within 72 hours, perform a complete history, physical, and liver biochemistries, including:  
New or worsening signs and symptoms of clinical hepatitis such as fatigue, nausea, vomiting, right 
upper quadrant pain or tenderness, fever, rash, or eosinophilia.  
Concomitant medications, including acetaminophen, dietary supplements, herbal remedies, over -the-
counter medications, recreational drug use, and special diets:  
• Alcohol consumption 
• Exposure to environmental chemical agents  
• Past medical history  
• Complete review of systems  
• Obtain liver biochemi stries including ALT, AST, alkaline phosphatase, total bilirubin, and INR.   
Evaluate subjects two or three times a week for signs and symptoms of clinical hepatitis and liver 
biochemistries until biochemistries stabilize.  
If biochemistries stabilize and the subject is asymptomatic, monitor liver biochemistries once a week until they return to baseline.  
Subjects who liver far from study sites can be evaluated locally for history, physical exam, and 
laboratories, if the resu lts are communicated promptly to the site investigator.  
  
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 66 of 93 APPENDIX D:  ALCOHOL QUESTIONNAIRE (AUDIT)  
 
 
 The Alcohol Use Disorders Identification TestI:nterview Version  
Read questions as written. Record answers carefull .yBegin the AUDIT by saying  
“ Now I am going to ask you some questions about your use of alcoholic beverages 
during this past year.” Explain what is meant by “ alcoholic beverages” by using 
local examples of beer, wine, vodka, etc. Code answers in terms of “ standard 
drinks” . Place the correct answer number in the box at the right.  
 
1. How often do you have a drink containin g alco- 
hol? 
(0) Never [Skip to Qs 9-10] 
(1) Monthly or  less 
(2) 2 to 4 times a month  
(3) 2 to 3 times a week  
(4) 4 or more times a week  
 
 
2. How many drinks containing alcohol do you have 
on a typical day when you are drinking?  
(0) 1 or 2 
(1) 3 or 4 
(2) 5 or  6 
(3) 7, 8, or  9 
(4) 10 or more  
 
3. How often do you have six or more drinks on one 
occasion?  
(0) Never  
(1) Less than monthly  
(2) Monthly  
(3) Weekly  
(4) Daily or almost  daily 
Skip to Questions 9 and 10 if Total Score 
for Questions 2 and 3 = 0  
 
4. How often during the last year have you found 
that you were not able to stop drinking once you 
had started?  
(0) Never  
(1) Less than monthly  
(2) Monthly  
(3) Weekly  
(4) Daily or almost  daily 
 
5. How often during the last year have you failed to 
do what was normally expected  from you 
because of drinking?  
(0) Never  
(1) Less than monthly  
(2) Monthly  
(3) Weekly  
(4) Daily or almost  daily 6. How often during the last year have you needed 
a first drink in the morning to get yourself going 
after a heavy drinking  session?  
(0) Never  
(1) Less than monthly  
(2) Monthly  
(3) Weekly  
(4) Daily or almost  daily 
 
7. How often during the last year have you had a 
feeling of guilt or remorse after drinking?  
(0) Never  
(1) Less than monthly  
(2) Monthly  
(3) Weekly  
(4) Daily or almost  daily 
 
8. How often during the last year have you been 
unable to remember what happened the night 
before because you had been  drinking?  
(0) Never  
(1) Less than monthly  
(2) Monthly  
(3) Weekly  
(4) Daily or almost  daily 
 
 
9. Have you or someone else been injured as a 
result of your  drinking?  
(0) No 
(2) Yes, but not in the last year 
(4) Yes, during the last year 
 
 
 
10. Has a relative or friend or a doctor or another 
health worker been concerned about your drink - 
ing or suggested you cut  down?  
(0) No  
(2) Yes, but not in the last year  
(4) Yes, during the last year  
 
Record total of specific items here 
If total is greater than recommended cut -off, consult User’s Manual.  
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 67 of 93 APPENDIX D:  Alcohol Questionnaire (AUDIT)  
 
 

LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 68 of 93 APPENDIX D:  Alcohol Questionnaire – AUDIT -C 
 
 
 
Patient Name Date of Visit  _ 
 
1. How often do you have a drink containing  alcohol?   a. Never  
 b. Monthly or less  
 c. 2-4 times a month  
 d. 2-3 times a week  
 e. 4 or more times a week  
 
2. How many standard drinks containing alcohol do you have on a typical  day?  
 a. 1 or  2 
 b. 3 or 4 
 c. 5 or 6 
 d. 7 to 9 
 e. 10 or more 
3. How often do you have six or more drinks on one  occasion?  
a. Never  
b. Less than monthly  
c. Monthly  
 d. Weekly  
e. Daily or almost daily  
 
        

LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 69 of 93 APPENDIX D:  Alcohol Questionnaire -  Skinner  
 
 
 
    
      

LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 70 of 93  
APPENDIX E:  FUNCTIONAL ACTIVITY QUESTIONNAIRE  (NHANES)  
 
NHANES 2017  
PAQ.605  Next I am going to ask you about the time {you spend/SP spends} doing different types of physical activity in a 
typical week.  
 
Think first about the time {you spend/he spends/she spends} doing work. Think of work as the things that  
{you have/he has/she has} to do such as paid or unpaid work, household chores, and yard work.  
 Does {your/SP’s} work involve vigorous -intensity activity that causes large increases in breathing or heart 
rate like carrying or lifting heavy loads, digging or construction work for at least 10 minutes continuously ? 
 
 
 
PAQ.610  In a typical week, on how many days {do you/does SP} do vigorous -intensity activities as part of {your/his/her} 
work?  
 
PROBE IF NEEDED: Vigorous -intensity activity causes large increases in breathing or heart rate and is done 
for at least 10 minutes contin uously . 
 
INTERVIEWER: REMEMBER, WE ARE ONLY ASKING ABOUT WORK AND CHORES IN THIS QUESTION.  
HARD EDIT: 1 -7. 
ERROR MESSAGE: THE NUMBER OF DAYS SHOULD BE BETWEEN 1 AND 7.  
|      |      |  
ENTER NUMBER OF DAYS  
REFUSED ..................................................... 77  (PAQ.620)  
DON'T KNOW ............................................... 99  (PAQ.620)  
 
PAQ.615  How much time {do you/does SP} spend doing vigorous -intensity activities at work on a typical day? 
Q/U 
 
PROBE IF NEEDED: Think about a typical day when {you do/he does/she does} vigorous -intensity activities 
during {your/his/her} work.  
 
PROBE IF NEEDED: Vigorous -intensity activity causes large increases in breathing or heart rate and is 
done for at least 10 minutes continuously.  
INTERVIEWER: REMEMBER, WE ARE ONLY ASKING ABOUT WORK AND CHORES. 
SOFT EDIT: >4 HOURS.  
ERROR MESSAGE: INTERVIEWER, YOU HAVE RECORDED THAT THE SP SPENDS MORE THAN 4  
HOURS DOING VIGOROUS -INTENSITY ACTIVITIES AT WORK ON A TYPICAL DAY. PLEASE CONFIRM 
WITH SP THAT OVER 4 HOURS IS CORRECT.  
 
HARD EDIT: > 24 HOURS. 
HARD EDIT: <10 MINUTES.  
ERROR MESSAGE: THE TIME SHOULD BE 10 MINUTES OR MORE, BUT LESS THAN 24 HOURS.  
 
|      |      |     |  
ENTER NUMBER OF MINUTES OR HOURS  
 YES ...............................................................  1  
NO .................................................................  2 (PAQ.620)  
REFUSED .....................................................  7 (PAQ.620)  
DON'T KNOW ...............................................  9 (PAQ.620)  
 
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 71 of 93 REFUSED ................................................. 7777 (PAQ.620)  
 
 
APPENDIX E:  con’t.  
DON'T KNOW ........................................... 9999 (PAQ.620)  
ENTER UNIT  
MINUTES ...................................................... 1 
HOURS ......................................................... 2 
PAQ.620  Does {your/SP’s} work involve moderate- intensity activity that causes small increases in breathing or heart 
rate such as bri sk walking or carrying light loads for at least 10 minutes continuously?  
 
YES ...............................................................  1  
NO .................................................................  2 (PAQ.635)  
REFUSED .....................................................  7 (PAQ.635)  
DON'T KNOW ...............................................  9 (PAQ.635)  
 
 
PAQ.625  In a typical week, on how many days {do you/does SP} do moderate -intensity activities as part of  
{your/his/her} work?  
 
PROBE IF NEEDED: Moderate -intensity activity causes small increases in breathing or heart rate and is 
done for at least 10 minutes continuously.  
INTERVIEWER: REMEMBER, WE ARE ONLY ASKING ABOUT WORK AND CHORES. 
HARD EDIT: 1 -7. 
ERROR MESSAGE: THE NUMBER OF D AYS SHOULD BE BETWEEN 1 AND 7.  
 
|      |      |  
ENTER NUMBER OF DAYS  
 
REFUSED ..................................................... 77  (PAQ.635)  
DON'T KNOW ............................................... 99  (PAQ.635)  
 
PAQ.630  How much time {do you/does SP} spend doing moderate-intensity activities at work on a typical day? 
Q/U 
 
PROBE IF NEEDED: Think about a typical day when {you do/he does/she does} moderate- intensity 
activities during {your/his/her} work.  
 
PROBE IF NEEDED: Mo derate-intensity activity causes small increases in breathing or heart rate and is 
done for at least 10 minutes continuously.  
INTERVIEWER: REMEMBER, WE ARE ONLY ASKING ABOUT WORK AND CHORES. 
SOFT EDIT: >4 HOURS.  
ERROR MESSAGE: INTERVIEWER, YOU HAVE RECORDED THAT THE SP SPENDS MORE THAN 4  
HOURS DOING MODERATE -INTENSITY ACTIVITIES AT WORK ON A TYPICAL DAY. PLEASE 
CONFIRM WITH SP THAT OVER 4 HOURS IS CORRECT.  
 
HARD EDIT: > 24 HOURS. 
HARD EDIT: <10 MINUTES.  
ERROR MESSAGE: THE TIME SHOULD BE 10 MINUTES OR MORE, BUT LESS THAN 24 HOURS.  
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 72 of 93  
APPENDIX E:  con’t.  
 
|      |      |     |  
ENTER NUMBER OF MINUTES OR HOURS  
 
REFUSED ................................................. 7777  (PAQ.635)  
DON'T KNOW ........................................... 9999  (PAQ.635)  
 
|      | 
ENTER UNIT  
MINUTES ...................................................... 1 
HOURS ......................................................... 2 
 
 
PAQ.635  The next questions exclude the physical activities at work that you have already mentioned. Now I would like 
to ask you about the usual way {you travel/SP travels} to and from places. For example to work, for shopping, 
to school.  
 
In a typical week {do you/does SP} walk or use a bicycle for at least 10 minutes continuously to get to and 
from places? 
 
YES ...............................................................  1  
NO .................................................................  2 (PAQ.650)  
REFUSED .....................................................  7 (PAQ.650)  
DON'T KNOW ...............................................  9 (PAQ.650)  
 
PAQ.640  In a typical week, on how many days {do you/does SP} walk or bicycle for at least 10 minutes continuously  
to get to and from places?  
 
HARD EDIT: 1 -7. 
ERROR MESSAGE: THE NUMBER OF DAYS SHOULD BE BETWEEN 1 AND 7.  
 
|      |      |  
ENTER NUMBER OF DAYS  
 
REFUSED .................................................. 77(PAQ.650)  
DON'T KNOW ............................................ 99(PAQ.650)  
 
PAQ.645  How much time {do you/does SP} spend walking or bicycling for travel on a typical day? 
Q/U 
 
PROBE IF NEEDED: Think about a typical day when {you walk or bicycle/SP walks or bicycles} for travel.  
 
SOFT EDIT: >4 HOURS.  
ERROR MESSAGE: INTERVIEWER, YOU HAVE RECORDED THAT THE SP SPENDS MORE THAN 4 
HOURS WALKING OR BICYCLING TO GET TO AND FROM PLACES ON A TYPICAL DAY. PLEASE 
CONFIRM WITH SP THAT OVER 4 HOURS IS CORRECT.  
 
HARD EDIT: > 24 HOURS. 
HARD EDIT: <10 MINUTES.  
ERROR MESSAGE: THE TIME SHOULD BE 10 MINUTES OR MORE, BUT LESS THAN 24 HOURS.  
 
|      |      |     |  
ENTER NUMBER OF MINUTES OR HOURS  
 
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 73 of 93  
APPENDIX E:  con’t.  
 
REFUSED ................................................. 7777  (PAQ.650)  
DON'T KNOW ........................................... 9999  (PAQ.650)  
 
|      | 
ENTER UNIT  
MINUTES ...................................................... 1 
HOURS ......................................................... 2 
 
 
 
PAQ.650  The next questions exclude the work and transportation activities that you have already mentioned. Now I 
would like to ask you about sports, fitness and recreational activities.  
 
In a typical week {do you/does SP} do any vigorous -intensity sports, fitness, or recreational activities that 
cause large increases in breathing or  heart rate like running or  basketball for  at least  10 minutes 
continuously ? 
 
YES ...............................................................  1  
NO .................................................................  2 (PAQ.665)  
REFUSED .....................................................  7 (PAQ.665)  
DON'T KNOW ...............................................  9 (PAQ.665)  
 
PAQ.655  In a typical week, on how many days {do you/does SP} do vigorous -intensity sports, fitness or recreational 
activities?  
 
PROBE IF NEEDED: Vigorous -intensity activity causes large increases in breathing or heart rate and is done 
for at least 10 minutes continuously.  
 
HARD EDIT: 1 -7. 
ERROR MESSAGE: THE NUMBER OF DAYS SHOULD BE BETWEEN 1 AND 7.  
 
|      |      |  
ENTER NUMBER OF DAYS  
 
REFUSED ..................................................... 77  (PAQ.665)  
DON'T KNOW ............................................... 99  (PAQ.665)  
 
 
PAQ.660   How much time {do you/does SP} spend doing vigorous –intensity sports, fitness or recreational activities on a 
typical day? 
 
PROBE IF NEEDED: Think about a typical day when {you do/SP does} vigorous -intensity sports, fitness or 
recreational activities.  
 
SOFT EDIT: >4 HOURS.  
ERROR MESSAGE: INTERVIEWER, YOU HAVE RECORDED THAT THE SP SPENDS MORE THAN 4 
HOURS DOING VIGOROUS -INTENSITY RECREATIONAL ACTIVITIES ON A TYPICAL DAY. PLEASE 
CONFIRM WITH SP THAT OVER 4 HOURS IS CORRECT.  
 
Q/U 
 
 
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 74 of 93  
APPENDIX E:  con’t.  
 
 
HARD EDIT: > 24 HOURS. 
HARD EDIT: <10 MINUTES.  
ERROR MESSAGE: THE TIME SHOULD BE 10 MINUTES OR MORE, BUT LESS THAN 24 HOURS.  
 
| | | | 
ENTER NUMBER OF MINUTES OR HOURS  
 
REFUSED ................................................. 7777  (PAQ.665)  
DON'T KNOW ........................................... 9999  (PAQ.665)  
 
| | 
ENTER UNIT  
MINUTES ...................................................... 1 
HOURS ......................................................... 2 
 
 
PAQ.665  In a typical week {do you/does SP} do any moderate-intensity sports, fitness, or recreational activities that 
cause a small increase in breathing or heart rate such as brisk walking, bicycling, swimming, or golf for at 
least 10 minutes continuously ? 
 
YES ...............................................................  1  
NO .................................................................  2 (PAQ.680)  
REFUSED .....................................................  7 (PAQ.680)  
DON'T KNOW ...............................................  9 (PAQ.680)  
 
PAQ.670  In a typical week, on how many days {do you/does SP} do moderate -intensity sports, fitness or recreational 
activities?  
 
PROBE IF NEEDED: Moderate -intensity sports, fitness or recreational activities cause small increases in 
breathing or heart rate and is done for at least 10 minutes continuously.  
 
HARD EDIT: 1 -7. 
ERROR MESSAGE: THE NUMBER OF DAYS SHOULD BE BETWEEN 1 AND 7.  
 
| | | 
ENTER NUMBER OF DAYS   
REFUSED .....................................................  77 (PAQ.680)  
DON'T KNOW ...............................................  99 (PAQ.680)  
 
Page 6 of 268  
 
PAQ.675  
Q/U 
 
How much time {do you/does SP} spend doing moderate-intensity sports, fitness or recreational activities on a 
typical day? 
 
PROBE IF NEEDED: Think about a typical day when {you do/SP does} moderate-intensity sports, fitness or 
recreational activities.  
 
 
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 75 of 93  
APPENDIX E:  con’t . 
 
PROBE IF NEEDED: Moderate -intensity sports, fitness or recreational activities cause small increases in 
breathing or heart rate and is done for at least 10 minutes continuously.  
 
SOFT EDIT: >4 HOURS.  
ERROR MESSAGE: INTERVIEWER, YOU HAVE RECORDED THAT THE SP SPENDS MORE THAN 4 
HOURS DOING MODERATE -INTENSITY RECREATIONAL ACTIVITIES ON A TYPICAL DAY. PLEASE 
CONFIRM WITH SP THAT OVER 4 HOURS IS CORRECT.  
 
HARD EDIT: > 24 HOURS. 
HARD EDIT: <10 MINUTES.  
ERROR MESSAGE: THE TIME SHOULD BE 10 MINUTES OR MORE, BUT  LESS THAN 24 HOURS.  
 
| | | | 
ENTER NUMBER OF MINUTES OR HOURS  
 
REFUSED ................................................. 7777  (PAQ.680)  
DON'T KNOW ........................................... 9999  (PAQ.680)  
 
| | 
ENTER UNIT  
MINUTES ...................................................... 1 
HOURS ......................................................... 2 
 
PAQ.680  
Q/U 
 
The following question is about sitting at work, at home, getting to and from places, or with friends, including 
time spent sitting at a desk, traveling in a car or bus, reading, playing cards, watching television, or using a 
computer. Do not include time spent sleeping.  
 
How much time {do you/does SP} usually spend sitting on a typical day?  
 
| | | | 
ENTER NUMBER OF MINUTES OR HOURS  
 
REFUSED ................................................. 7777 (BOX  2) 
DON'T KNOW ........................................... 9999 (BOX  2) 
 
| | 
ENTER UNIT  
 
MINUTES ...................................................... 1 
HOURS ......................................................... 2 
 
SOFT EDIT: 18 HOURS OR MORE.  
ERROR MESSAGE: PLEASE VERIFY TIMES OF 18 HOURS OR MORE.  
 
HARD EDIT: 24 HOURS OR MORE.  
ERROR MESSAGE: TH E TIME SHOULD BE LESS THAN 24 HOURS.  
 
 
 
 
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 76 of 93  
APPENDIX E:  con’t . 
 
 
 
 
PAQ.706  Now I'd like to ask you some questions about {your/SP's} activities.  
 
During the past 7 days, on how many days {were you/was SP} physically active for a total of at least 60 
minutes per day ?  Add up all the time {you/he/she} spent in any kind of physical activity that increased  
{your/his/her} heart rate and made {you/him/her} breathe hard some of  the time.  
 
0 days............................................................ 0 
1 day.............................................................. 1 
2 days............................................................ 2 
3 days............................................................ 3 
4 days............................................................ 4 
5 days............................................................ 5 
6 days............................................................ 6 
7 days............................................................ 7 
REFUSED ..................................................... 77 
DON’T KNOW ............................................... 99 
PAQ.710  Now I will ask you first about TV watching and then about computer use.  
Over the past 30 days, on average how many hours per day did {you/SP} sit and watch TV or videos? 
Would you say . . .  
less than 1 hour, ............................................ 0 
1 hour, ........................................................... 1  
2 hours, ......................................................... 2 
3 hours, ......................................................... 3 
4 hours, ......................................................... 4 
5 hours or more, or ........................................ 5 
{You do/SP does} not watch TV or videos.....  8 
REFUSED ..................................................... 77 
DON'T KNOW ............................................... 99 
PAQ.715  Over the past 30 days, on average how many hours per day did {you/SP} use a computer or play computer 
games outside of school? Include time spent on things such as Xbox, PlayStation, an iPod, an iPad or other  
 BOX 
2 
CHECK ITEM PAQ.720:  
IF SP AGE 18+, GO TO NEXT SECTION.  
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 77 of 93 APPENDIX E:  con’t . 
 
tablet, a smart phone, YouTube, Facebook or other social networking tools, and the internet. Would you 
say 
. . . 
less than 1 hour, ............................................ 0 
1 hour, ........................................................... 1  
2 hours, ......................................................... 2 
3 hours, ......................................................... 3 
4 hours, ......................................................... 4 
5 hours or more, or ........................................ 5 
{You do/SP does} not use a computer  
  outside of work or school ............................   8  
REFUSED ..................................................... 77 
DON'T KNOW ............................................... 99 
HELP SCREEN:  
If the SP watches T.V. or video at the same time as working on the computer, count this time as 
watching T.V.  
or video.  
 
 
            
   
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 78 of 93 APPENDIX F:  INTERNATIONAL -PROSTATE SYMPTOM SCORE (I -
PSS) QUESTIONNAIRE  
 
 
  INTERNATIONAL -PROSTATE SYMPTOM SCORE (I -PSS)  
   
 
Not at  all  
Less Than 
1 Time in 5  Less Than 
Half the 
Time   
About Half 
the Time  More Than 
Half the 
Time   
Almost 
Always  
 
1 Over the past month, how often 
have you had a sensation of not 
emptying your bladder completely 
after you finished urinating?   
0  
1  
2  
3  
4  
5 
 
2 Over the past month, how often 
have you had to urinate again less 
than two hours after you finished 
urinating?   
0  
1  
2  
3  
4  
5 
 
3 Over the past month, how often 
have you found you stopped and 
started again several times when 
you urinated?   
0  
1  
2  
3  
4  
5 
 
4 Over the past month, how often 
have you found it difficult to 
postpone urination?   
0  
1  
2  
3  
4  
5 
 
5 Over the past month, how often 
have you had a weak urinary 
stream?   
0  
1  
2  
3  
4  
5 
 
6 Over the past month, how often 
have you had to push or strain to 
begin urination?   
0  
1  
2  
3  
4  
5 
   
None   
1 time   
2 times   
3 times   
4 times  5 or more  
times  
 
 
7 Over the past month, how many 
times did you most typically get up 
to urinate from the time you went 
to bed at night until the time you 
got up in the morning?   
 
0  
 
1  
 
2  
 
3  
 
4  
 
5 
 
Total I -PSS Score S =  
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 79 of 93 APPENDIX F. International -Prostate Symptom Score (I -PSS) (CONTINUED)  
 
QUALITY OF LIFE DUE TO URINARY SYMPTOMS  
  
 
 
 
Delighted   
 
 
 
Pleased   
 
 
Mostly 
Satisfied  Mixed 
About 
Equally 
Satisfied 
and 
Dissatisfied   
 
 
Mostly 
Dissatisfied   
 
 
 
Unhappy   
 
 
 
Terrible  
 
 
1 If you were to spend 
the rest of your life 
with your urinary 
condition just the way 
it is now, how would  
  you feel about  that?    
 
0  
 
1  
 
2  
 
3  
 
4  
 
5  
 
6 
 
Quality of life assessment index L =  
 
International – Prostate Symptom Score © (I-PSS ©) Michael J. Barry, 1992. All rights reserved.  
 
 
            
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 80 of 93 APPENDIX G:  HR -QOL (SF -36) QUESTIONNAIRE  
 
 

LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 81 of 93 APPENDIX G:  con’t.  
 

LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 82 of 93 APPENDIX G:  con’t.  
 

LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 83 of 93 APPENDIX G:  con’t.  
 

LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 84 of 93 APPENDIX G:  con’t.  
 

LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 85 of 93 APPENDIX H:  PGI-S QUESTIONNAIRE  
 
PGI Scales PGI-S (Severity) Scale  
Please choose the response below that best describes the severity of your 
symptoms over the past 4 weeks.  
1. None.  
2. Mild.  
3. Moderate.  
4. Severe.  
5. Very severe.  
 
             
    
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 86 of 93 APPENDIX I:  PGI- C QUESTIONNAIRE  
 
PGI-C (Change) Scale  
Please choose the response below that best describes the overall change in your 
symptoms since you started using the study treatment.  
1. Very much better.  
2. Moderately better.  
3. A little better.  
4. No change.  
5. A little worse.  
6. Moderately worse.  
7. Very much worse  
 
             
   
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 87 of 93 APPENDIX J:  CHRONIC LIVER DISEASE QUESTIONNAIRE (CLDQ)   
THE CHRONIC LIVER DISEASE QUESTIONNAIRE  
(CLDQ) —QUALITY OF LIFE INDEX FOR PATIENTS  WITH CHRONIC LIVER DISEASE  
This questionnaire is designed to find out how you have  been feeling during the last two weeks. 
You will be asked about your symptoms related to your liver disease, how  you have been 
affected in doing activities, and how your  mood has been. Please complete all of the questions 
and select only one response for each question.  
RESPONSE OPTIONS  
1 All of the time  
2 Most of the time  
3 A good bit of the time  
4 Some of the time  
5 A little of the time  
6 Hardly any of the time  
7 None of the time  
QUESTIONS  
1. How much of the time during the last two weeks  have you been troubled by a feeling of 
abdominal  bloating?  
2. How much of the time have you been tired or  fatigued during the last two weeks?  
3. How much of the time during the last two weeks  have you experienced bodily pain?  
4. How often during the last two weeks have you felt  sleepy during the day?  
5. How much of the time during the last two weeks  have you experienced abdominal pain?  
6. How much of the time during the last two weeks  has shortness of breath been a problem for 
you in your daily activities?  
7. How much of the time during the last two weeks  have you not been able to eat as much as you 
would like?   
8. How much of the time in the last two weeks have  you been bothered by having decreased 
strength?  
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 88 of 93 9. How often during the last two weeks have you had trouble lifting or carrying heavy objects?  
10. How often during the last two weeks have you felt  anxious?  
11. How often during the last two weeks have you felt a  decreased level of energy?  
12. How much of the time during the last two weeks  have you felt unhappy?  
13. How often during the last two weeks have you felt  drowsy?  
14. How much of the time during the last two weeks  have you been bothered by a limitation of 
your diet?  
15. How often during the last two weeks have you been  irritable?  
16. How much of the time during the last two weeks  have you had difficulty sleeping at night?  
17. How much of the time during the last two weeks  have you been troubled by a feeling of 
abdominal  discomfort?  
18. How much of the time during the  last two weeks have  you been worried about the impact 
your liver disease  has on your family?  
19. How much of the time during the last two weeks  have you had mood swings?  
20. How much of the time during the last two weeks  have you been unable to fall aslee p at night?  
21. How often during the last two weeks have you had muscle cramps?  
22. How much of the time during the last two weeks  have you been worried that your symptoms 
will develop into major problems?  
23. How much of the time during the last two weeks  have you had a dry mouth?  
24. How much of the time during the last two weeks  have you felt depressed?  
25. How much of the time during the last two weeks  have you been worried about your condition 
getting  worse?  
26. How much of the time during the last two weeks  have you had problems concentrating?  
27. How much of the time have you been troubled by itching during the last two weeks?  
28. How much of the time during the last two weeks  have you been worried about never feeling 
any better?  
29. How much of the t ime during the last two weeks  have you been concerned about the 
availability of a  liver if you need a liver transplant?  
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 89 of 93 APPENDIX K:  SEXUAL DESIRE AND DISTRESS QUESTIONNAIRE  
 
PROVIDE A 7- PAGE PRINTOUT OF THE FOLLOWING QUESTION FOR SUBJECTS 
TO COMPLETE DURING SCREENING , AND PRIOR TO  WEEKS 4, 8, 12, 16, 20, 24, 
30, AND 36.  
Sexual Desire Question: Daily Rating  
Instructions:  Please read the item below carefully and circle the number that best  describes how 
you feel.  Circle only one number.   
 
How would you rate your level (degree) of sexual desire today? 
0 1 2 3 4 5 
None at all  Very low  Low Moderate  High  Very high  
 
 
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 90 of 93 PROVIDE A SINGLE PAGE PRINTOUT OF THE FOLLOWING QUESTION FOR 
SUBJECTS TO COMPLETE DURING  SCREENING , AND PRIOR TO  WEEKS 4, 8, 12, 
16, 20, 24, 30, AND 36.  
Sexual D istress  Question: Weekly Rating 
Instructions:  Please read the item below carefully and circle the number that best describes how 
you feel.  Circle only one number. Rate how much the problem listed below has bothered you 
over the past 7 days , including today.  
 
How often did you feel: Bothered by low sexual desire?  
Past 7 Days  0 1 2 3 4 
Never  Rarely  Occasionally  Frequently  Always  
 
  
           
  
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 92 of 93 13 REFERENCES  
i Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non- alcoholic fatty liver disease: 
practice Guideline by the American Association for the Study of Liver Diseases, American College of 
Gastroenterology, and the American Gastroenterological Association.  Hepatology.  2012; 55:2005 –2023.  
ii Loomba R, Sanyal AJ. The global NAFLD epidemic.  Nat Rev Gastroenterol Hepatol.  2013; 10:686 –690. 
iii Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non- alcoholic 
fatty liver disease and non- alcoholic steatohepatitis in adults.  Aliment Pharmacol Ther.  2011; 34:274 –285. 
iv Fraser A, Longnecker MP, Lawlor DA. Prevalence of elevated alanine aminotransferase among US adolescents 
and associated factors: NHANES 1999 –2004.  Gastroenterology.  2007; 133:1814– 1820.   
v Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic 
steatohepatitis among a largel y middle -aged population utilizing ultrasound and liver biopsy: a prospective 
study.  Gastroenterology.  2011; 140:124 –131. 
vi Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population -based 
cohort study.  Gastroenterology.  2005;129:113– 121. 
vii Bhala N, Angulo P, van der Poorten D, et al. The natural history of nonalcoholic fatty liver disease with 
advanced fibrosis or cirrhosis: an international collaborative study.  Hepatology.  
viii Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis Progression in Nonalcoholic Fatty 
Liver vs Nonalcoholic Steatohepatitis: A Systematic Review and Meta -analysis of Paired -Biopsy Studies.  Clin 
Gastroenterol Hepatol.  2014  
ix Teli MR, James OF, Burt AD, Bennett MK, Day CP. T he natural history of nonalcoholic fatty liver: a follow -up 
study.  Hepatology.  1995;22:1714– 1719.  
x Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a 
longitudinal study of 103 patients with sequentia l liver biopsies.  J Hepatol.  2005;42:132– 138. 
xi Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a 
spectrum of clinical and pathological severity.  Gastroenterology.  1999; 116:1413– 1419.  
xii McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of NAFLD progression from 
steatosis to fibrosing -steatohepatitis using paired biopsies: Implications for prognosis and clinical management.  J 
Hepatol.  2015; 62:1148– 1155.  
xiii Singh S, Al len AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis Progression in Nonalcoholic Fatty 
Liver vs Nonalcoholic Steatohepatitis: A Systematic Review and Meta -analysis of Paired -Biopsy Studies.  Clin 
Gastroenterol Hepatol.  2014  
xiv  Pais R, Charlotte F, Fedchu k L, et al. A systematic review of follow -up biopsies reveals disease progression in 
patients with non -alcoholic fatty liver.  J Hepatol.  2013; 59:550 –556. 
xv Loomba R, Abraham M, Unalp A, et al. Association between diabetes, family history of diabetes, and r isk of 
nonalcoholic steatohepatitis and fibrosis.  Hepatology.  2012; 56:943 –951. 
xvi Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American 
Heart Association/National Heart, Lung, and Blood Institute Scientific Statement.  Circulation.  2005; 112:2735– 2752.  
xvii Noureddin M, Yates KP, Vaughn IA, et al. Clinical and histological determinants of nonalcoholic 
steatohepatitis and advanced fibrosis in elderly patients.  Hepatology.  2013; 58:1644 –1654.  
xviii Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic 
steatohepatitis among a largely middle -aged population utilizing ultrasound and liver biopsy: a prospective 
study.  Gastroenterology.  2011; 140:124 –131. 
xix Wong VW, Wong GL, Choi PC, et al. Disease progression of non- alcoholic fatty liver disease: a prospective 
study with paired liver biopsies at 3 years.  Gut. 2010; 59:969– 974. 
xx Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non -alcoholic 
fatty liver disease and non- alcoholic steatohepatitis in adults.  Aliment Pharmacol Ther.  2011; 34:274 –285. 
xxi Fassio E, Alvarez E, Dominguez N, Landeira G, Longo C. Natural history of nonalcoholic steatohepatitis: a 
longitudinal study of repeat  liver biopsies.  Hepatology.  2004; 40:820 –826.  
xxii Argo CK, Northup PG, Al -Osaimi AM, Caldwell SH. Systematic review of risk factors for fibrosis progression 
in non -alcoholic steatohepatitis.  J Hepatol.  2009; 51:371 –379. 
  
 
LPCN 1144 (Testosterone Undecanoate for NASH)  Version 3.0 
Protocol LPCN 1144- 18-002 7 January 2020  
 Confidential  Page 93 of 93  
 
xxiii Wong VW, Wong GL, Choi PC, et al. Di sease progression of non- alcoholic fatty liver disease: a prospective 
study with paired liver biopsies at 3 years.  Gut. 2010; 59:969– 974.  
xxiv Hamaguchi E, Takamura T, Sakurai M, et al. Histological course of nonalcoholic fatty liver disease in Japanese 
patie nts: tight glycemic control, rather than weight reduction, ameliorates liver fibrosis.  Diabetes 
Care.  2010; 33:284 –286.  
xxv Neuschwander -Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic 
Conference.  Hepatology.  2003; 37:120 2–1219.  
xxvi Wong RJ, Cheung R, Ahmed A. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver 
transplantation in patients with hepatocellular carcinoma in the U.S.  Hepatology.  2014; 59:2188 –2195.  
xxvii  Wong RJ, Aguilar M, Cheung R, et al. Nonalcoholic Steatohepatitis Is the Second Leading Etiology of Liver 
Disease Among Adults Awaiting Liver Transplantation in the United States.  Gastroenterology.  2014  
xxviii  Hashimoto E, Yatsuji S, Tobari M, et al. Hepatocellular carcinoma in patients with nonalcoholic 
steatohepatitis.  J Gastroenterol.  2009; 44(Suppl 19):89 –95. 
xxix Sanyal  A.J, Calsani  N., Kowdley  K.V.  et al. Pioglitazone,  Vitamin  E, or Placebo  for Nonalcoholic  Steatohepatitis.  
N Engl J Med 2010;362:1675- 1685  
xxx Bendich A, Machlin LJ. Safety of oral intake of vitamin E. Am J Clin Nutr 1988; 48(3):612- 619. 
xxxi Machlin LJ. Use and safety of elevated dosages of vitamin E in adults. Int J Vitam Nutr Res Suppl 1989; 30:56-
68. 
xxxii   Testos terone  stopping criteria based on guidance from the FDA received 7 -15-19 and 8 -15-19. 
xxxiii  Bendich A, Machlin LJ. Safety of oral intake of vitamin E. Am J Clin Nutr 1988; 48(3):612- 619. 
xxxiv Machlin LJ. Use and safety of elevated dosages of vitamin E in adults. Int J Vitam Nutr Res Suppl 1989; 
30:56- 68. 
xxxv Bhasin S , Brito JP, Cunningham GR, et al. Testosterone therapy in men with androgen deficiency syndromes: 
An endocrine society clinical practice guideline. J Clin Endcocrinol Metab. 2018. Doi: 10.1210/jc.2018- 00229 
xxxvi Mederacke I, Wursthorn K, Kirschner J, Rifa i K, Manns MP, Wedemeyer H, Bahr MJ, Food intake increase 
liver stiffness in patients with chronic or resolved hepatitis C virus infection. Liver International 2009; 29:1500-
1506  
xxxvii Arena U, Lupsor Platon M, Stasi C, Moscarella S, Assarat A, Bedogni G,  Piazzolla V, et el. Liver stiffness is 
influenced by a standardized meal in patient with chronic hepatitis C virus at different stages of fibrotic evolution. Hepatology 2013;58:65: -75 
 
 
 
       